Copyright and Permissions

©ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre) 2022

All rights reserved. HPV Information Centre publications can be obtained from the HPV Information Centre Secretariat, Institut Català d’Oncologia, Avda. Gran Via de l’Hospitaltalet, 199-203 08908 L’Hospitalet del Llobregat (Barcelona) Spain. E-mail: hpvcentre@iconcologia.net. Requests for permission to reproduce or translate HPV Information Centre publications - whether for sale or for non-commercial distribution- should be addressed to the HPV Information Centre Secretariat, at the above address. Any digital or printed publication of the information provided in the web site should be accompanied by an acknowledgment of HPV Information Centre as the source.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part the HPV Information Centre concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended the HPV Information Centre in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the HPV Information Centre to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the HPV Information Centre be liable for damages arising from its use.

Recommended citation:


ICO/IARC HPV Information Centre
Executive summary

Human papillomavirus (HPV) infection is now a well-established cause of cervical cancer and there is growing evidence of HPV being a relevant factor in other anogenital cancers (anus, vulva, vagina and penis) and head and neck cancers. HPV types 16 and 18 are responsible for about 70% of all cervical cancer cases worldwide. HPV vaccines that prevent against HPV 16 and 18 infection are now available and have the potential to reduce the incidence of cervical and other anogenital cancers.

This report provides key information for Finland on cervical cancer, other anogenital cancers and head and neck cancers, HPV-related statistics, factors contributing to cervical cancer, cervical cancer screening practices, and HPV vaccine introduction. The report is intended to strengthen the guidance for health policy implementation of primary and secondary cervical cancer prevention strategies in the country.
# Table 1: Key Statistics in Finland

**Population**

| Women at risk for cervical cancer (Female population aged >=15 yrs) | 2.37 million |

**Burden of cervical cancer and other HPV-related cancers**

| Annual number of cervical cancer cases | 185 |
| Annual number of cervical cancer deaths | 67 |

<table>
<thead>
<tr>
<th>Crude incidence rates per 100,000 population:</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical cancer</td>
<td>-</td>
<td>6.59</td>
</tr>
<tr>
<td>Anal cancer</td>
<td>0.77</td>
<td>0.96</td>
</tr>
<tr>
<td>Vulva cancer</td>
<td>-</td>
<td>3.77</td>
</tr>
<tr>
<td>Vaginal cancer</td>
<td>-</td>
<td>0.89</td>
</tr>
<tr>
<td>Penile cancer</td>
<td>1.46</td>
<td>-</td>
</tr>
<tr>
<td>Oropharyngeal cancer</td>
<td>5.89</td>
<td>1.92</td>
</tr>
<tr>
<td>Oral cavity cancer</td>
<td>7.83</td>
<td>6.27</td>
</tr>
<tr>
<td>Laryngeal cancer</td>
<td>3.73</td>
<td>0.53</td>
</tr>
</tbody>
</table>

**Burden of cervical HPV infection**

Prevalence (%) of HPV 16 and/or HPV 18 among women with:

<table>
<thead>
<tr>
<th>Normal cytology</th>
<th>3.8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-grade cervical lesions (LSIL/CIN-1)</td>
<td>27.1</td>
</tr>
<tr>
<td>High-grade cervical lesions (HSIL/CIN-2/CIN-3/CIS)</td>
<td>54.5</td>
</tr>
<tr>
<td>Cervical cancer</td>
<td>88.5</td>
</tr>
</tbody>
</table>

**Other factors contributing to cervical cancer**

| Smoking prevalence (%) [95% UI], women | 15.3 [12.2-18.3] |
| Total fertility rate (live births per women) | 1.8 |
| Oral contraceptive use (%) | 35.8 |
| HIV prevalence (%) [95% UI], women (15-49 years) | <0.1 [<0.1 -<0.1] |

**Sexual behaviour**

| Percentage of 15-year-old who have had sexual intercourse (men/women) | 25.0/24.0 |
| Range of median age at first sexual intercourse (men/women) | 17.3-18.8/16.6-20.7 |

**Cervical screening practices and recommendations**

| Cervical cancer screening coverage, % (age and screening interval, reference) | 66.8% (All women aged 30-60 screened every 1y, EUROSTAT Finland) |
| Screening ages (years) | 30-60 |
| Screening interval (years) or frequency of screens | 5 years |

**HPV vaccine in females**

<table>
<thead>
<tr>
<th>HPV vaccination programme</th>
<th>Introduced</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year of introduction</td>
<td>2013</td>
</tr>
<tr>
<td>HPV coverage – first dose (%) (estimation year 2019)</td>
<td>60</td>
</tr>
<tr>
<td>HPV coverage – last dose (%) (estimation year 2019)</td>
<td>60</td>
</tr>
<tr>
<td>HPV coverage – first dose (%) (estimation year 2020)</td>
<td>-</td>
</tr>
<tr>
<td>HPV coverage – last dose (%) (estimation year 2020)</td>
<td>-</td>
</tr>
</tbody>
</table>

* Please see the specific sections for more information.
Contents

Executive summary iii

1 Introduction 2

2 Demographic and socioeconomic factors 4

3 Burden of HPV related cancers 5
   3.1 HPV related cancers incidence 5
   3.2 HPV related cancers mortality 7
   3.3 Cervical cancer
      3.3.1 Cervical cancer mortality in Finland 9
      3.3.2 Cervical cancer incidence by histology in Finland 12
      3.3.3 Cervical cancer mortality in Finland 15
      3.3.4 Cervical cancer incidence and mortality comparison in Finland 17
   3.4 Anogenital cancers other than the cervix 19
      3.4.1 Anal cancer
         3.4.1.1 Anal cancer incidence in Finland 19
         3.4.1.2 Anal cancer mortality in Finland 21
         3.4.1.3 Anal cancer incidence and mortality comparison in Finland 23
      3.4.2 Vulva cancer
         3.4.2.1 Vulva cancer incidence in Finland 24
         3.4.2.2 Vulva cancer mortality in Finland 26
         3.4.2.3 Vulva cancer incidence and mortality comparison in Finland 28
      3.4.3 Vaginal cancer
         3.4.3.1 Vaginal cancer incidence in Finland 29
         3.4.3.2 Vaginal cancer mortality in Finland 31
         3.4.3.3 Vaginal cancer incidence and mortality comparison in Finland 33
      3.4.4 Penile cancer
         3.4.4.1 Penile cancer incidence in Finland 34
         3.4.4.2 Penile cancer mortality in Finland 36
         3.4.4.3 Penile cancer incidence and mortality comparison in Finland 38
   3.5 Head and neck cancers 39
      3.5.1 Oropharyngeal cancer
         3.5.1.1 Oropharyngeal cancer incidence in Finland 39
         3.5.1.2 Oropharyngeal cancer mortality in Finland 41
         3.5.1.3 Oropharyngeal cancer incidence and mortality comparison in Finland 43
      3.5.2 Oral cavity cancer
         3.5.2.1 Oral cavity cancer incidence in Finland 44
         3.5.2.2 Oral cavity cancer incidence and mortality comparison in Finland 46
         3.5.2.3 Oral cavity cancer incidence and mortality comparison in Finland 48
      3.5.3 Laryngeal cancer
         3.5.3.1 Laryngeal cancer incidence in Finland 49
         3.5.3.2 Laryngeal cancer incidence and mortality comparison in Finland 51
         3.5.3.3 Laryngeal cancer incidence and mortality comparison in Finland 53

4 HPV related statistics 54
   4.1 HPV burden in women with normal cervical cytology, cervical precancerous lesions or invasive cervical cancer 54
      4.1.1 HPV prevalence in women with normal cervical cytology 55
      4.1.2 HPV type distribution among women with normal cervical cytology, precancerous cervical lesions and cervical cancer 56
      4.1.3 HPV type distribution among HIV+ women with normal cervical cytology 66
LIST OF CONTENTS

- vi -

4.1.4 Terminology ......................................................... 67
4.2 HPV burden in anogenital cancers other than cervix .......... 68
  4.2.1 Anal cancer and precancerous anal lesions .............. 69
  4.2.2 Vulvar cancer and precancerous vulvar lesions ........... 71
  4.2.3 Vaginal cancer and precancerous vaginal lesions ......... 73
  4.2.4 Penile cancer and precancerous penile lesions .......... 75
4.3 HPV burden in men ...................................................... 77
4.4 HPV burden in the head and neck .................................. 78
  4.4.1 Burden of oral HPV infection in healthy population .... 78
  4.4.2 HPV burden in head and neck cancers .................... 79

5 Factors contributing to cervical cancer .......................... 81

6 Sexual and reproductive health behaviour indicators ............ 83

7 HPV preventive strategies ............................................. 86
  7.1 Cervical cancer screening practices .......................... 86
  7.2 HPV vaccination ...................................................... 90
    7.2.1 HPV vaccination in Finland, by region ................. 90

8 Protective factors for cervical cancer ............................ 91

9 Annex ........................................................................ 92
  9.1 Incidence .............................................................. 92
    9.1.1 Cervical cancer incidence in Finland across Northern Europe .... 92
    9.1.2 Anal cancer incidence in Finland across Northern Europe .... 95
    9.1.3 Vulva cancer incidence in Finland across Northern Europe .... 100
    9.1.4 Vaginal cancer incidence in Finland across Northern Europe .. 103
    9.1.5 Penile cancer incidence in Finland across Northern Europe .... 106
    9.1.6 Oropharyngeal cancer incidence in Finland across Northern Europe .. 109
    9.1.7 Oral cavity cancer incidence in Finland across Northern Europe .. 114
    9.1.8 Laryngeal cancer incidence in Finland across Northern Europe .. 119
  9.2 Mortality .............................................................. 124
    9.2.1 Cervical cancer mortality in Finland across Northern Europe .. 124
    9.2.2 Anal cancer mortality in Finland across Northern Europe .... 127
    9.2.3 Vulva cancer mortality in Finland across Northern Europe .... 132
    9.2.4 Vaginal cancer mortality in Finland across Northern Europe .... 135
    9.2.5 Penile cancer mortality in Finland across Northern Europe .... 138
    9.2.6 Oropharyngeal cancer mortality in Finland across Northern Europe .. 141
    9.2.7 Oral cavity cancer mortality in Finland across Northern Europe .... 146
    9.2.8 Laryngeal cancer mortality in Finland across Northern Europe .... 151

10 Glossary .................................................................. 156
List of Figures

1. Finland and Northern Europe .................................................... 2
2. Population pyramid of Finland for 2019 ..................................... 4
3. Population trends in four selected age groups in Finland ............. 4
4. Comparison of HPV related cancers incidence to other cancers in men and women of all ages in Finland (estimates for 2020) 5
5. Comparison of HPV related cancers incidence to other cancers among men and women 15-44 years of age in Finland (estimates for 2020) 5
6. Comparison of HPV related cancers mortality to other cancers in men and women of all ages in Finland (estimates for 2020) 6
7. Comparison of HPV related cancers mortality to other cancers among men and women 15-44 years of age in Finland (estimates for 2020) 7
8. Age-specific incidence rates of cervical cancer in Finland (estimates for 2020) ......................................................... 8
9. Annual number of new cases of cervical cancer in Finland (estimates for 2020) ......................................................... 11
10. Time trends in cervical cancer incidence in Finland (cancer registry data) .............................................................. 14
11. Age-specific mortality rates of cervical cancer in Finland (estimates for 2020) ......................................................... 16
12. Annual number of deaths of cervical cancer in Finland (estimates for 2020) ......................................................... 16
13. Comparison of age-specific cervical cancer incidence and mortality rates in Finland (estimates for 2020) 17
14. Comparison of annual premature deaths and disability from cervical cancer in Finland to other cancers among women (estimates for 2019) 18
15. Age-specific incidence rates of anal cancer in Finland (estimates for 2020) ......................................................... 20
16. Annual number of new cases of anal cancer in Finland (estimates for 2020) ......................................................... 20
17. Age-specific mortality rates of anal cancer in Finland (estimates for 2020) ......................................................... 22
18. Annual number of deaths of anal cancer in Finland (estimates for 2020) ......................................................... 22
19. Comparison of age-specific anal cancer incidence and mortality rates among men in Finland (estimates for 2020) 23
20. Comparison of age-specific anal cancer incidence and mortality rates among women in Finland (estimates for 2020) 23
21. Age-specific incidence rates of vulva cancer in Finland (estimates for 2020) ......................................................... 25
22. Annual number of new cases of vulva cancer in Finland (estimates for 2020) ......................................................... 25
23. Age-specific mortality rates of vulva cancer in Finland (estimates for 2020) ......................................................... 27
24. Annual number of deaths of vulva cancer in Finland (estimates for 2020) ......................................................... 27
25. Comparison of age-specific vulva cancer incidence and mortality rates in Finland (estimates for 2020) 28
26. Age-specific incidence rates of vaginal cancer in Finland (estimates for 2020) ......................................................... 30
27. Annual number of new cases of vaginal cancer in Finland (estimates for 2020) ......................................................... 30
28. Age-specific mortality rates of vaginal cancer in Finland (estimates for 2020) ......................................................... 32
29. Annual number of deaths of vaginal cancer in Finland (estimates for 2020) ......................................................... 32
30. Comparison of age-specific vaginal cancer incidence and mortality rates in Finland (estimates for 2020) 33
31. Age-specific incidence rates of penile cancer in Finland (estimates for 2020) ......................................................... 35
32. Annual number of new cases of penile cancer in Finland (estimates for 2020) ......................................................... 35
33. Age-specific mortality rates of penile cancer in Finland (estimates for 2020) ......................................................... 37
34. Annual number of deaths of penile cancer in Finland (estimates for 2020) ......................................................... 37
35. Comparison of age-specific penile cancer incidence and mortality rates in Finland (estimates for 2020) 38
36. Age-specific incidence rates of oropharyngeal cancer in Finland (estimates for 2020) ......................................................... 40
37. Annual number of new cases of oropharyngeal cancer in Finland (estimates for 2020) ......................................................... 40
38. Age-specific mortality rates of oropharyngeal cancer in Finland (estimates for 2020) ......................................................... 42
39. Annual number of deaths of oropharyngeal cancer in Finland (estimates for 2020) ......................................................... 42
40. Comparison of age-specific oropharyngeal cancer incidence and mortality rates among men in Finland (estimates for 2020) 43
41. Comparison of age-specific oropharyngeal cancer incidence and mortality rates among women in Finland (estimates for 2020) 43
42. Age-specific incidence rates of oral cavity cancer in Finland (estimates for 2020) ......................................................... 45
43. Annual number of new cases of oral cavity cancer in Finland (estimates for 2020) ......................................................... 45
44. Age-specific mortality rates of oral cavity cancer in Finland (estimates for 2020) ......................................................... 47
45. Annual number of deaths of oral cavity cancer in Finland (estimates for 2020) ......................................................... 47
46. Comparison of age-specific oral cavity cancer incidence and mortality rates among men in Finland (estimates for 2020) 48
47. Comparison of age-specific oral cavity cancer incidence and mortality rates among women in Finland (estimates for 2020) 48
48. Age-specific incidence rates of laryngeal cancer in Finland (estimates for 2020) ......................................................... 48
49. Annual number of new cases of laryngeal cancer in Finland (estimates for 2020) ......................................................... 50
50. Age-specific mortality rates of laryngeal cancer in Finland (estimates for 2020) ......................................................... 52
51. Annual number of deaths of laryngeal cancer in Finland (estimates for 2020) ......................................................... 52
52. Comparison of age-specific laryngeal cancer incidence and mortality rates among men in Finland (estimates for 2020) 53
53 Comparison of age-specific laryngeal cancer incidence and mortality rates among women in Finland (estimates for 2020) .......................................................... 53
54 Crude age-specific HPV prevalence (%) and 95% confidence interval in women with normal cervical cytology in Finland .......................................................... 55
55 HPV prevalence among women with normal cervical cytology in Finland, by study ....................................................................................................................... 55
56 HPV 16 prevalence among women with normal cervical cytology in Finland, by study ............................... 56
57 HPV 16 prevalence among women with low-grade cervical lesions in Finland, by study .............................. 57
58 HPV 16 prevalence among women with high-grade cervical lesions in Finland, by study .............................. 57
59 HPV 16 prevalence among women with invasive cervical cancer in Finland, by study ........................................ 58
60 Comparison of the ten most frequent HPV oncogenic types in Finland among women with and without cervical lesions ........................................ 59
61 Comparison of the ten most frequent HPV oncogenic types in Finland among women with invasive cervical cancer by histology ........................................ 61
62 Comparison of the ten most frequent HPV types in anal cancer cases in Europe and the World ................... 70
63 Comparison of the ten most frequent HPV types in AIN 2/3 cases in Europe and the World ....................... 70
64 Comparison of the ten most frequent HPV types in cases of vulvar cancer in Europe and the World ........... 72
65 Comparison of the ten most frequent HPV types in VIN 2/3 cases in Europe and the World ...................... 72
66 Comparison of the ten most frequent HPV types in cases of vaginal cancer in Europe and the World ........ 74
67 Comparison of the ten most frequent HPV types in VaIN 2/3 cases in Europe and the World .................... 74
68 Comparison of the ten most frequent HPV types in cases of penile cancer in Europe and the World .......... 76
69 Comparison of the ten most frequent HPV types in PeIN 2/3 cases in Europe and the World .................... 76
70 Annual number of new cases of cervical cancer by age group in Finland (estimates for 2020) .................. 93
71 Comparison of age-specific cervical cancer incidence rates in Finland, within the region, and the rest of world ................................. 94
72 Age-standardised incidence rates of cervical cancer of Finland (estimates for 2020) ......................... 94
73 Annual number of new cases of cervical cancer by age group in Finland (estimates for 2020) .................. 95
74 Comparison of age-specific cervical cancer incidence rates in Finland, within the region, and the rest of world ................................. 94
75 Age-standardised incidence rates of anal cancer of Finland (estimates for 2020) ......................... 95
76 Annual number of new cases of anal cancer among men by age group in Finland (estimates for 2020) .... 96
77 Annual number of new cases of anal cancer among women by age group in Finland (estimates for 2020) .... 97
78 Comparison of age-specific anal cancer incidence rates among men by age in Finland, within the region, and the rest of world ........................................ 98
79 Comparison of age-specific anal cancer incidence rates among women by age in Finland, within the region, and the rest of world ........................................ 99
80 Age-standardised incidence rates of vulva cancer of Finland (estimates for 2020) ................................. 100
81 Annual number of new cases of vulva cancer by age group in Finland (estimates for 2020) ..................... 101
82 Comparison of age-specific vulva cancer incidence rates in Finland, within the region, and the rest of world ................................. 102
83 Age-standardised incidence rates of vaginal cancer of Finland (estimates for 2020) ................................. 103
84 Annual number of new cases of cervical cancer by age group in Finland (estimates for 2020) .................. 104
85 Comparison of age-specific vaginal cancer incidence rates in Finland, within the region, and the rest of world ................................. 105
86 Age-standardised incidence rates of penile cancer of Finland (estimates for 2020) ................................. 106
87 Annual number of new cases of penile cancer by age group in Finland (estimates for 2020) ..................... 107
88 Comparison of age-specific penile cancer incidence rates in Finland, within the region, and the rest of world ................................. 108
89 Age-standardised incidence rates of oropharyngeal cancer of Finland (estimates for 2020) .................... 109
90 Annual number of new cases of oropharyngeal cancer among men by age group in Finland (estimates for 2020) ................................. 110
91 Annual number of new cases of oropharyngeal cancer among women by age group in Finland (estimates for 2020) ................................. 111
92 Comparison of age-specific oropharyngeal cancer incidence rates among men by age in Finland, within the region, and the rest of world ........................................ 112
93 Comparison of age-specific oropharyngeal cancer incidence rates among women by age in Finland, within the region, and the rest of world ........................................ 113
94 Age-standardised incidence rates of oral cavity cancer of Finland (estimates for 2020) ........................... 114
95 Annual number of new cases of oral cavity cancer among men by age group in Finland (estimates for 2020) ................................. 115
96 Annual number of new cases of oral cavity cancer among women by age group in Finland (estimates for 2020) ................................. 116
97 Comparison of age-specific oral cavity cancer incidence rates among men by age in Finland, within the region, and the rest of world ........................................ 117
98 Comparison of age-specific oral cavity cancer incidence rates among women by age in Finland, within the region, and the rest of world ........................................ 118
99 Age-standardised incidence rates of laryngeal cancer of Finland (estimates for 2020) ............................ 119
100 Annual number of new cases of laryngeal cancer among men by age group in Finland (estimates for 2020) ................................. 120
101 Annual number of new cases of laryngeal cancer among women by age group in Finland (estimates for 2020) ................................. 121
102 Comparison of age-specific laryngeal cancer incidence rates among men by age in Finland, within the region, and the rest of world ........................................ 122
103 Comparison of age-specific laryngeal cancer incidence rates among women by age in Finland, within the region, and the rest of world ........................................ 123
104 Age-standardised mortality rates of cervical cancer of Finland (estimates for 2020) ............................ 124
LIST OF FIGURES

105 Annual number of deaths of cervical cancer by age group in Finland (estimates for 2020) .......................... 125
106 Comparison of age-specific cervical cancer mortality rates in Finland, within the region, and the rest of world 126
107 Age-standardised mortality rates of anal cancer of Finland (estimates for 2020) ................................. 127
108 Annual number of deaths of anal cancer among men by age group in Finland (estimates for 2020) .......... 128
109 Annual number of deaths of anal cancer among women by age group in Finland (estimates for 2020) ...... 129
110 Comparison of age-specific anal cancer mortality rates among men by age in Finland, within the region, and the rest of world .......................................................... 130
111 Comparison of age-specific anal cancer mortality rates among women by age in Finland, within the region, and the rest of world .......................................................... 131
112 Age-standardised mortality rates of vulva cancer of Finland (estimates for 2020) ................................. 132
113 Annual number of deaths of vulva cancer by age group in Finland (estimates for 2020) ...................... 133
114 Comparison of age-specific vulva cancer mortality rates in Finland, within the region, and the rest of world 134
115 Age-standardised mortality rates of vaginal cancer of Finland (estimates for 2020) .............................. 135
116 Annual number of deaths of cervical cancer by age group in Finland (estimates for 2020) .................. 136
117 Comparison of age-specific vaginal cancer mortality rates in Finland, within the region, and the rest of world 137
118 Age-standardised mortality rates of penile cancer of Finland (estimates for 2020) ............................... 138
119 Annual number of new deaths of penile cancer by age group in Finland (estimates for 2020) .......... 139
120 Comparison of age-specific penile cancer mortality rates in Finland, within the region, and the rest of world 140
121 Age-standardised mortality rates of oropharyngeal cancer of Finland (estimates for 2020) ............... 141
122 Annual number of deaths of oropharyngeal cancer among men by age group in Finland (estimates for 2020) 142
123 Annual number of deaths of oropharyngeal cancer among women by age group in Finland (estimates for 2020) 143
124 Comparison of age-specific oropharyngeal cancer mortality rates among men by age in Finland, within the region, and the rest of world .................................................. 144
125 Comparison of age-specific oropharyngeal cancer mortality rates among women by age in Finland, within the region, and the rest of world .................................................. 145
126 Age-standardised mortality rates of oral cavity cancer of Finland (estimates for 2020) ....................... 146
127 Annual number of deaths of oral cavity cancer among men by age group in Finland (estimates for 2020) 147
128 Annual number of deaths of oral cavity cancer among women by age group in Finland (estimates for 2020) 148
129 Comparison of age-specific oral cavity cancer mortality rates among men by age in Finland, within the region, and the rest of world .................................................. 149
130 Comparison of age-specific oral cavity cancer mortality rates among women by age in Finland, within the region, and the rest of world .................................................. 150
131 Age-standardised mortality rates of laryngeal cancer of Finland (estimates for 2020) ......................... 151
132 Annual number of deaths of laryngeal cancer among men by age group in Finland (estimates for 2020) 152
133 Annual number of deaths of laryngeal cancer among women by age group in Finland (estimates for 2020) 153
134 Comparison of age-specific laryngeal cancer mortality rates among men by age in Finland, within the region, and the rest of world .................................................. 154
135 Comparison of age-specific laryngeal cancer mortality rates among women by age in Finland, within the region, and the rest of world .................................................. 155
# List of Tables

1. Key Statistics in Finland ........................................ iv
2. Cervical cancer incidence in Finland (estimates for 2020) .......... 9
3. Cervical cancer incidence in Finland by cancer registry .......... 10
4. Age-standardised incidence rates of cervical cancer in Finland by histological type and cancer registry .... 12
5. Cervical cancer mortality in Finland (estimates for 2020) ...... 15
6. Premature deaths and disability from cervical cancer in Finland, Europe and the rest of the world (estimates for 2019) .... 17
7. Anal cancer incidence in Finland (estimates for 2020) .......... 19
8. Anal cancer mortality in Finland (estimates for 2020) .......... 21
9. Vulva cancer incidence in Finland (estimates for 2020) ... 24
10. Vulva cancer mortality in Finland (estimates for 2020) .... 26
11. Vaginal cancer incidence in Finland (estimates for 2020) .. 29
12. Vaginal cancer mortality in Finland (estimates for 2020) ... 31
13. Penile cancer incidence in Finland (estimates for 2020) .... 34
14. Penile cancer mortality in Finland (estimates for 2020) .... 36
15. Oropharyngeal cancer incidence in Finland (estimates for 2020) ... 39
16. Oropharyngeal cancer mortality in Finland (estimates for 2020) .. 41
17. Oral cavity cancer incidence in Finland (estimates for 2020) .... 44
18. Oral cavity cancer mortality in Finland (estimates for 2020) ... 46
19. Laryngeal cancer incidence in Finland (estimates for 2020) ... 49
20. Laryngeal cancer mortality in Finland (estimates for 2020) ... 51
21. Prevalence of HPV16 and HPV18 by cytology in Finland .... 56
22. Type-specific HPV prevalence in women with normal cervical cytology, precancerous cervical lesions and invasive cervical cancer in Finland .... 63
23. Type-specific HPV prevalence among invasive cervical cancer cases in Finland by histology ... 65
24. Studies on HPV prevalence among HIV+ women with normal cytology in Finland .... 66
25. Studies on HPV prevalence among anal cancer cases in Finland (male and female) ... 69
26. Studies on HPV prevalence among anal cancer cases in Finland (male) ... 69
27. Studies on HPV prevalence among vulvar cancer cases in Finland ... 71
28. Studies on HPV prevalence among VIN 2/3 cases in Finland .... 71
29. Studies on HPV prevalence among vaginal cancer cases in Finland ... 73
30. Studies on HPV prevalence among VaIN 2/3 cases in Finland .... 73
31. Studies on HPV prevalence among penile cancer cases in Finland ... 75
32. Studies on HPV prevalence among PeIN 2/3 cases in Finland ... 75
33. Studies on HPV prevalence among men in Finland ... 77
34. Studies on HPV prevalence among men from special subgroups in Finland ... 77
35. Studies on oral HPV prevalence among healthy in Finland ... 78
36. Studies on HPV prevalence among cases of oral cavity cancer in Finland ... 79
37. Studies on HPV prevalence among cases of oropharyngeal cancer in Finland ... 79
38. Studies on HPV prevalence among cases of hypopharyngeal or laryngeal cancer in Finland ... 81
39. Factors contributing to cervical carcinogenesis (cofactors) in Finland ... 83
40. Percentage of 15-year-olds who have had sexual intercourse in Finland ... 83
41. Median age at first sex in Finland ... 83
42. Marriage patterns in Finland ... 84
43. Average number of sexual partners in Finland ... 84
44. Lifetime prevalence of anal intercourse among women in Finland ... 85
45. Main characteristics of cervical cancer screening in Finland ... 86
46. Estimated coverage of cervical cancer screening in Finland ... 86
47. Estimated coverage of cervical cancer screening in Finland, by region ... 89
48. National HPV Immunization programme in Finland ... 90
49. National HPV Immunization programme in - (Finland) ... 90
50. Prevalence of male circumcision in Finland ... 91
51. Prevalence of condom use in Finland ... 91
52. Glossary ... 156
1 Introduction

Figure 1: Finland and Northern Europe

Information Centre aims to compile and centralise updated data and statistics on human papillomavirus (HPV) and related cancers. This report aims to summarise the data available to fully evaluate the burden of disease in Finland and to facilitate stakeholders and relevant bodies of decision makers to formulate recommendations on the prevention of cervical cancer and other HPV-related cancers. Data include relevant cancer statistic estimates, epidemiological determinants of cervical cancer such as demographics, socioeconomic factors, risk factors, burden of HPV infection in women and men, cervical screening and immunization practices. The report is structured into the following sections:

Section 2, Demographic and socioeconomic factors. This section summarises the socio-demographic profile of Finland. For analytical purposes, Finland is classified in the geographical region of Northern Europe (Figure 1, lighter blue), which is composed of the following countries: Åland Islands, Channel Islands, Denmark, Estonia, Faeroe Islands, United Kingdom of Great Britain and Northern Ireland, Guernsey, Isle of Man, Ireland, Iceland, Jersey, Lithuania, Latvia, Norway, Svalbard and Jan Mayen Islands, and Sweden. Throughout the report, Finland estimates will be complemented with corresponding regional estimates.

Section 3, Burden of HPV related cancers. This section describes the current burden of invasive cervical cancer and other HPV-related cancers in Finland with estimates of prevalence, incidence, and mortality rates. Information in other HPV-related cancers includes other anogenital cancers (anus, vulva, vagina, and penis) and head and neck cancers (oral cavity, oropharyngeal, and larynx).

Section 4, HPV related statistics. This section reports on prevalence of HPV and HPV type-specific distribution in Finland, in women with normal cytology, precancerous lesions and invasive cervical cancer. In addition, the burden of HPV in other anogenital cancers (anus, vulva, vagina, and penis), head and neck cancers (oral cavity, oropharynx, and larynx) and men are presented.

Section 5, Factors contributing to cervical cancer. This section describes factors that can modify
the natural history of HPV and cervical carcinogenesis such as smoking, parity, oral contraceptive use, and co-infection with HIV.

Section 6, **Sexual and reproductive health behaviour indicators.** This section presents sexual and reproductive behaviour indicators that may be used as proxy measures of risk for HPV infection and anogenital cancers, such as age at first sexual intercourse, average number of sexual partners, and anal intercourse among others.

Section 7, **HPV preventive strategies.** This section presents preventive strategies that include basic characteristics and performance of cervical cancer screening status, status of HPV vaccine licensure introduction, and recommendations in national immunisation programmes.

Section 8, **Protective factors for cervical cancer.** This section presents male circumcision and the use of condoms.
2 Demographic and socioeconomic factors

Figure 2: Population pyramid of Finland for 2019

Figure 3: Population trends in four selected age groups in Finland

Data accessed on 15 Jul 2019
Including Åland Islands.
Please refer to original source for methods of estimation.
Year of estimate: 2019
Data Source:
3 Burden of HPV related cancers

HPV is the cause of almost all cervical cancer cases and is responsible for an important fraction of other anogenital and head and neck cancer. Here, we present the most recent estimations on the burden of HPV-associated cancer.

3.1 HPV related cancers incidence

Figure 4: Comparison of HPV related cancers incidence to other cancers in men and women of all ages in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data sources-methods

Non-melanoma skin cancer is not included
Rates per 100,000 men per year.
Rates per 100,000 women per year.

Figure 5: Comparison of HPV related cancers incidence to other cancers among men and women 15-44 years of age in Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Males Rate</th>
<th>Females Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>9.07</td>
<td>1.87</td>
</tr>
<tr>
<td>Melanoma of skin</td>
<td>2.51</td>
<td>14.9</td>
</tr>
<tr>
<td>Thyroid</td>
<td>3.66</td>
<td>4.37</td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>4.14</td>
<td>10.07</td>
</tr>
<tr>
<td>Colon and rectum cancer</td>
<td>3.57</td>
<td>3.15</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>3.95</td>
<td>2.24</td>
</tr>
<tr>
<td>Ovary</td>
<td>2.51</td>
<td>1.93</td>
</tr>
<tr>
<td>Brain, nervous system</td>
<td>1.12</td>
<td>0.10</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>1.35</td>
<td>0.91</td>
</tr>
<tr>
<td>Leukaemia</td>
<td>2.12</td>
<td>0.81</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>0.19</td>
<td>0.61</td>
</tr>
<tr>
<td>Lung</td>
<td>0.39</td>
<td>0.61</td>
</tr>
<tr>
<td>Kidney</td>
<td>1.06</td>
<td>0.51</td>
</tr>
<tr>
<td>Salivary glands</td>
<td>0.77</td>
<td>0.51</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.68</td>
<td>0.30</td>
</tr>
<tr>
<td>Lip, oral cavity*</td>
<td>0.60</td>
<td>0.30</td>
</tr>
<tr>
<td>Stomach</td>
<td>0.00</td>
<td>0.10</td>
</tr>
<tr>
<td>Oropharynx*</td>
<td>0.10</td>
<td>0.10</td>
</tr>
<tr>
<td>Anus*</td>
<td>0.39</td>
<td>0.10</td>
</tr>
<tr>
<td>Bladder</td>
<td>0.48</td>
<td>0.30</td>
</tr>
<tr>
<td>Nasopharynx*</td>
<td>0.00</td>
<td>0.10</td>
</tr>
<tr>
<td>Ovary*</td>
<td>0.39</td>
<td>0.10</td>
</tr>
<tr>
<td>Liver</td>
<td>0.00</td>
<td>0.10</td>
</tr>
<tr>
<td>Gallbladder*</td>
<td>0.00</td>
<td>0.10</td>
</tr>
<tr>
<td>Vagina*</td>
<td>0.00</td>
<td>0.10</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>0.19</td>
<td>0.10</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Oesophagus</td>
<td>0.10</td>
<td>0.00</td>
</tr>
<tr>
<td>Larynx*</td>
<td>0.10</td>
<td>0.00</td>
</tr>
<tr>
<td>Mesothelioma</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
<td>0.10</td>
<td>0.00</td>
</tr>
<tr>
<td>Penis*</td>
<td>0.00</td>
<td>0.10</td>
</tr>
<tr>
<td>Prostate</td>
<td>0.10</td>
<td>0.00</td>
</tr>
<tr>
<td>Testis</td>
<td>1.49</td>
<td></td>
</tr>
</tbody>
</table>

Annual crude incidence rate per 100,000 Finland: Male and female (All ages)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-source-methods
Non-melanoma skin cancer is not included
Rates per 100,000 men per year.
Rates per 100,000 women per year.

Data Sources:
3.2 HPV related cancers mortality

Figure 6: Comparison of HPV related cancers mortality to other cancers in men and women of all ages in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-source-methods
Non-melanoma skin cancer is not included
Rates per 100,000 men per year.
Rates per 100,000 women per year.
Data Sources

ICO/IARC HPV Information Centre
Figure 7: Comparison of HPV related cancers mortality to other cancers among men and women 15-44 years of age in Finland (estimates for 2020)

![Comparison of HPV related cancers mortality to other cancers among men and women 15-44 years of age in Finland (estimates for 2020)](image-url)

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon and rectum cancer</td>
<td>3.66</td>
<td>4.37</td>
</tr>
<tr>
<td>Breast</td>
<td>3.05</td>
<td></td>
</tr>
<tr>
<td>Brain, nervous system</td>
<td>2.70</td>
<td>1.32</td>
</tr>
<tr>
<td>Cervix uteri*</td>
<td>0.91</td>
<td></td>
</tr>
<tr>
<td>Ovary</td>
<td>0.71</td>
<td></td>
</tr>
<tr>
<td>Stomach</td>
<td>0.39</td>
<td>0.51</td>
</tr>
<tr>
<td>Leukaemia</td>
<td>0.46</td>
<td>0.41</td>
</tr>
<tr>
<td>Lip, oral cavity*</td>
<td>0.19</td>
<td>0.30</td>
</tr>
<tr>
<td>Lung</td>
<td>0.77</td>
<td>0.20</td>
</tr>
<tr>
<td>Melanoma of skin</td>
<td>0.39</td>
<td>0.20</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>0.20</td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>0.39</td>
<td>0.20</td>
</tr>
<tr>
<td>Liver</td>
<td>0.39</td>
<td>0.10</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.19</td>
<td>0.10</td>
</tr>
<tr>
<td>Vagina*</td>
<td>0.10</td>
<td></td>
</tr>
<tr>
<td>Salivary glands</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Oropharynx*</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Oesophagus</td>
<td>0.19</td>
<td>0.00</td>
</tr>
<tr>
<td>Anus*</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Larynx*</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Mesothelioma</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Vulva*</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.29</td>
<td>0.00</td>
</tr>
<tr>
<td>Bladder</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Thyroid</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>0.19</td>
<td>0.00</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>0.10</td>
<td>0.00</td>
</tr>
<tr>
<td>Penis*</td>
<td>0.10</td>
<td>0.00</td>
</tr>
<tr>
<td>Prostate</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Testis</td>
<td>0.68</td>
<td>0.00</td>
</tr>
</tbody>
</table>

Annual crude mortality rate per 100,000
Finland: Female (15-44 years)

Data accessed on 27 Jan 2021
Non-melanoma skin cancer is not included
Rates per 100,000 men per year.
Rates per 100,000 women per year.

Data Sources:
3.3 Cervical cancer


This section describes the current burden of invasive cervical cancer in Finland and in comparison to geographic region, including estimates of the annual number of new cases, deaths, incidence, and mortality rates.

3.3.1 Cervical cancer incidence in Finland

**Key Stats.**

About 185 new cervical cancer cases are diagnosed annually in Finland (estimations for 2020).

Cervical cancer ranks* as the 17th leading cause of female cancer in Finland.

Cervical cancer is the 4th most common female cancer in women aged 15 to 44 years in Finland.

* Ranking of cervical cancer incidence to other cancers among all women according to highest incidence rates (ranking 1st) excluding non-melanoma skin cancer. Ranking is based on crude incidence rates (actual number of cervical cancer cases). Ranking using age-standardized rate (ASR) may differ.

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual number of new cancer cases</td>
<td>185</td>
<td>6,666</td>
<td>604,127</td>
</tr>
<tr>
<td>Uncertainty intervals of new cancer cases [95% UI]</td>
<td>[134-256]</td>
<td>[6,414-6,927]</td>
<td>[582,031-627,062]</td>
</tr>
<tr>
<td>Crude incidence rate</td>
<td>6.59</td>
<td>12.4</td>
<td>15.6</td>
</tr>
<tr>
<td>Age-standardized incidence rateb</td>
<td>5.23</td>
<td>10.4</td>
<td>13.3</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years olda</td>
<td>0.47</td>
<td>0.90</td>
<td>1.39</td>
</tr>
</tbody>
</table>

**Table 2: Cervical cancer incidence in Finland (estimates for 2020)**

aData accessed on 27 Jan 2021


b Rates per 100,000 women per year.

Data Sources

Table 3: Cervical cancer incidence in Finland by cancer registry

<table>
<thead>
<tr>
<th>Cancer registry</th>
<th>Period</th>
<th>N cases\textsuperscript{a}</th>
<th>Crude rate\textsuperscript{b}</th>
<th>ASR\textsuperscript{b}</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td>2003-2007</td>
<td>776</td>
<td>5.8</td>
<td>3.9</td>
</tr>
<tr>
<td>National\textsuperscript{c}</td>
<td>2003-2007</td>
<td>776</td>
<td>5.8</td>
<td>3.9</td>
</tr>
</tbody>
</table>

Data accessed on 5 Oct 2018

Please refer to original source (available at http://ci5.iarc.fr/CI5-XI/Default.aspx)

ASR: Age-standardized rate. Standardized rates have been estimated using the direct method and the World population as the reference.

\textsuperscript{a} Accumulated number of cases during the period in the population covered by the corresponding registry.
\textsuperscript{b} Rates per 100,000 women per year.
\textsuperscript{c} Data from CI5C volume X.

Data Sources:

Figure 8: Age-specific incidence rates of cervical cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

Data Sources:

Figure 9: Annual number of new cases of cervical cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

Data Sources:

- For age-standardised incidence rates of cervical cancer of Finland (estimates for 2020) please refer to Figure 72
- For annual number of new cases of cervical cancer by age group in Finland (estimates for 2020) please refer to Figure 73
- For comparison of age-specific cervical cancer incidence rates in Finland, within the region, and the rest of world please refer to Figure 74
### 3.3.2 Cervical cancer incidence by histology in Finland

Table 4: Age-standardised incidence rates of cervical cancer in Finland by histological type and cancer registry

<table>
<thead>
<tr>
<th>Cancer registry¹</th>
<th>Period</th>
<th>Squamo</th>
<th>Adeno</th>
<th>Other</th>
<th>Unspec.</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td>2003-2007</td>
<td>2.4</td>
<td>1.2</td>
<td>0.1</td>
<td>0.1</td>
</tr>
</tbody>
</table>

Data accessed on 5 Oct 2018

Rates per 100,000 women per year.

Standardized rates have been estimated using the direct method and the World population as the reference.

Adeno: adenocarcinoma; Other: Other carcinoma; Squamous: Squamous cell carcinoma; Unspec: Unspecified carcinoma;

Data Sources:

Data accessed on 28 Aug 2018

Data Sources

Figure 10: Time trends in cervical cancer incidence in Finland (cancer registry data)

No data available

No data available

No data available
3.3.3 Cervical cancer mortality in Finland

Key Stats.

About **67 cervical cancer deaths occur annually in Finland** are diagnosed **annually** (estimations for 2020).

Cervical cancer **ranks** as the **17th leading cause of cancer deaths** of female cancer deaths in **Finland**.

Cervical cancer is the **4th leading cause of cancer deaths** in women aged **15 to 44 years in Finland**.

* Ranking of cervical cancer incidence to other cancers among all women according to highest incidence rates (ranking 1st) excluding non-melanoma skin cancer. Ranking is based on crude incidence rates (actual number of cervical cancer cases). Ranking using age-standardized rate (ASR) may differ.

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual number of deaths</td>
<td>67</td>
<td>2,134</td>
<td>341,831</td>
</tr>
<tr>
<td>Uncertainty intervals of mortality cases [95% UI]</td>
<td>[51-88]</td>
<td>[1,984-2,296]</td>
<td>[324,231-360,386]</td>
</tr>
<tr>
<td>Crude mortality rate\textsuperscript{b}</td>
<td>2.39</td>
<td>3.97</td>
<td>8.84</td>
</tr>
<tr>
<td>Age-standardized mortality rate\textsuperscript{b}</td>
<td>1.12</td>
<td>2.18</td>
<td>7.25</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old\textsuperscript{a}</td>
<td>0.12</td>
<td>0.22</td>
<td>0.82</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

\textsuperscript{b} Rates per 100,000 women per year.

Data accessed on 27 Jan 2021

Data Sources:
Figure 11: Age-specific mortality rates of cervical cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more-detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources

• For age-standardised mortality rates of cervical cancer of Finland (estimates for 2020) please refer to Figure 104

• For annual number of deaths of cervical cancer by age group in Finland (estimates for 2020) please refer to Figure 105

• For comparison of age-specific cervical cancer mortality rates in Finland, within the region, and the rest of world please refer to Figure 106

ICO/IARC HPV Information Centre
3.3.4 Cervical cancer incidence and mortality comparison in Finland

Figure 13: Comparison of age-specific cervical cancer incidence and mortality rates in Finland (estimates for 2020)

Table 6: Premature deaths and disability from cervical cancer in Finland, Europe and the rest of the world (estimates for 2019)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Rate</th>
<th>Europe</th>
<th>Rate</th>
<th>World</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>Rate</td>
<td>Number</td>
<td>Rate</td>
<td>Number</td>
<td>Rate</td>
</tr>
<tr>
<td>DALYs (95% UI)</td>
<td>2,364</td>
<td>84 (63-96)</td>
<td>824,336</td>
<td>189</td>
<td>8,955,013</td>
<td>232</td>
</tr>
<tr>
<td></td>
<td>(1,776-2,960)</td>
<td></td>
<td>(726,198-913,992)</td>
<td>(166-209)</td>
<td>(7,547,733-9,978,462)</td>
<td>(198-259)</td>
</tr>
<tr>
<td>YLLs (95% UI)</td>
<td>2,253</td>
<td>80 (60-91)</td>
<td>793,756</td>
<td>182</td>
<td>8,712,962</td>
<td>226</td>
</tr>
<tr>
<td></td>
<td>(1,094-2,549)</td>
<td></td>
<td>(703,094-877,841)</td>
<td>(161-201)</td>
<td>(7,365,279-9,728,886)</td>
<td>(191-252)</td>
</tr>
<tr>
<td>YLDs (95% UI)</td>
<td>111 (70-164)</td>
<td>4 (3-6)</td>
<td>30,580</td>
<td>7 (5-10)</td>
<td>242,051</td>
<td>6 (4-8)</td>
</tr>
<tr>
<td></td>
<td>(21,266-42,064)</td>
<td></td>
<td>(171,644-326,024)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021


Data Sources:

Table 6: Premature deaths and disability from cervical cancer in Finland, Europe and the rest of the world (estimates for 2019)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Rate</th>
<th>Europe</th>
<th>Rate</th>
<th>World</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>Rate</td>
<td>Number</td>
<td>Rate</td>
<td>Number</td>
<td>Rate</td>
</tr>
<tr>
<td>DALYs (95% UI)</td>
<td>2,364</td>
<td>84 (63-96)</td>
<td>824,336</td>
<td>189</td>
<td>8,955,013</td>
<td>232</td>
</tr>
<tr>
<td></td>
<td>(1,776-2,960)</td>
<td></td>
<td>(726,198-913,992)</td>
<td>(166-209)</td>
<td>(7,547,733-9,978,462)</td>
<td>(198-259)</td>
</tr>
<tr>
<td>YLLs (95% UI)</td>
<td>2,253</td>
<td>80 (60-91)</td>
<td>793,756</td>
<td>182</td>
<td>8,712,962</td>
<td>226</td>
</tr>
<tr>
<td></td>
<td>(1,094-2,549)</td>
<td></td>
<td>(703,094-877,841)</td>
<td>(161-201)</td>
<td>(7,365,279-9,728,886)</td>
<td>(191-252)</td>
</tr>
<tr>
<td>YLDs (95% UI)</td>
<td>111 (70-164)</td>
<td>4 (3-6)</td>
<td>30,580</td>
<td>7 (5-10)</td>
<td>242,051</td>
<td>6 (4-8)</td>
</tr>
<tr>
<td></td>
<td>(21,266-42,064)</td>
<td></td>
<td>(171,644-326,024)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data accessed on 29 Apr 2021

Rate per 100,000 women

DALYs (95% UI): estimated disability adjusted life years (95% uncertainty interval)

YLLs (95% UI): years of life lost (95% uncertainty interval)

YLDs (95% UI): estimated years lived with disability (95% uncertainty interval)

Data Sources:
Figure 14: Comparison of annual premature deaths and disability from cervical cancer in Finland to other cancers among women (estimates for 2019)

Data accessed on 29 Apr 2021
YLLs: years of life lost
YLDs: years lived with disability

Data Sources:

ICO/IARC HPV Information Centre
3.4 Anogenital cancers other than the cervix

Data on HPV role in anogenital cancers other than cervix are limited, but there is an increasing body of evidence strongly linking HPV DNA with cancers of anus, vulva, vagina, and penis. Although these cancers are much less frequent compared to cervical cancer, their association with HPV make them potentially preventable and subject to similar preventative strategies as those for cervical cancer. (Vaccine 2006, Vol. 24, Suppl 3; Vaccine 2008, Vol. 26, Suppl 10; Vaccine 2012, Vol. 30, Suppl 5; IARC Monographs 2007, Vol. 90).

3.4.1 Anal cancer

Anal cancer is rare in the general population with an average worldwide incidence of 1 per 100,000, but is reported to be increasing in more developed regions. Globally, there are an estimated 29,000 new cases in 2018 every year (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Women have higher incidences of anal cancer than men. Incidence is particularly high among populations of men who have sex with men (MSM), women with history of cervical or vulvar cancer, and immunosuppressed populations, including those who are HIV-infected and patients with a history of organ transplantation. These cancers are predominantly squamous cell carcinoma, adenocarcinomas, or basaloid and cloacogenic carcinomas.

3.4.1.1 Anal cancer incidence in Finland

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of new cancer cases</td>
<td>21</td>
<td>750</td>
<td>21,706</td>
</tr>
<tr>
<td>Uncertainty intervals of new cancer cases [95% UI]</td>
<td>[13-33]</td>
<td>[676-832]</td>
<td>[18,432-25,561]</td>
</tr>
<tr>
<td>Crude incidence rate(^b)</td>
<td>0.77</td>
<td>1.43</td>
<td>0.55</td>
</tr>
<tr>
<td>Age-standardized incidence rate(^b)</td>
<td>0.40</td>
<td>0.79</td>
<td>0.49</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old(^a)</td>
<td>0.05</td>
<td>0.09</td>
<td>0.06</td>
</tr>
<tr>
<td>WOMEN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of new cancer cases</td>
<td>27</td>
<td>1,557</td>
<td>29,159</td>
</tr>
<tr>
<td>Uncertainty intervals of new cancer cases [95% UI]</td>
<td>[18-41]</td>
<td>[1,450-1,672]</td>
<td>[25,656-33,140]</td>
</tr>
<tr>
<td>Crude incidence rate(^c)</td>
<td>0.96</td>
<td>2.90</td>
<td>0.75</td>
</tr>
<tr>
<td>Age-standardized incidence rate(^c)</td>
<td>0.48</td>
<td>1.57</td>
<td>0.58</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old(^a)</td>
<td>0.06</td>
<td>0.19</td>
<td>0.07</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021


\(^a\) Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

\(^b\) Rates per 100,000 men per year.

\(^c\) Rates per 100,000 women per year.

Data Sources:

Figure 15: Age-specific incidence rates of anal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
* Rates per 100,000 men per year.
† Rates per 100,000 women per year.

Data Sources

Figure 16: Annual number of new cases of anal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources
### 3.4.1.2 Anal cancer mortality in Finland

Table 8: Anal cancer mortality in Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of new cancer cases</td>
<td>11</td>
<td>301</td>
<td>9,416</td>
</tr>
<tr>
<td>Uncertainty intervals of new cancer cases [95% UI]</td>
<td>[6-22]</td>
<td>[255-356]</td>
<td>[7,282-12,175]</td>
</tr>
<tr>
<td>Crude incidence rate&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.40</td>
<td>0.57</td>
<td>0.24</td>
</tr>
<tr>
<td>Age-standardized incidence rate&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.19</td>
<td>0.27</td>
<td>0.21</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.03</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>WOMEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of new cancer cases</td>
<td>11</td>
<td>452</td>
<td>9,877</td>
</tr>
<tr>
<td>Uncertainty intervals of new cancer cases [95% UI]</td>
<td>[6-21]</td>
<td>[395-518]</td>
<td>[7,795-12,516]</td>
</tr>
<tr>
<td>Crude incidence rate&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.39</td>
<td>0.84</td>
<td>0.26</td>
</tr>
<tr>
<td>Age-standardized incidence rate&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.17</td>
<td>0.33</td>
<td>0.19</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.02</td>
<td>0.04</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021


<sup>a</sup> Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

<sup>b</sup> Rates per 100,000 men per year.

<sup>c</sup> Rates per 100,000 women per year.

Data Sources:
Figure 17: Age-specific mortality rates of anal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
* Rates per 100,000 men per year.
* Rates per 100,000 women per year.

Data Sources:

Figure 18: Annual number of deaths of of anal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:
3.4.1.3 Anal cancer incidence and mortality comparison in Finland

Figure 19: Comparison of age-specific anal cancer incidence and mortality rates among men in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-source-methods
* Rates per 100,000 men per year.

Data Sources:

Figure 20: Comparison of age-specific anal cancer incidence and mortality rates among women in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-source-methods
* Rates per 100,000 women per year.

Data Sources:
3.4.2 Vulva cancer

Cancer of the vulva is rare among women worldwide, with an estimated 44,000 new cases in 2018, representing 6% of all gynaecologic cancers (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Worldwide, about 60% of all vulvar cancer cases occur in more developed countries. Vulvar cancer has two distinct histological patterns with two different risk factor profiles: (1) basaloid/warty types (2) keratinising types. Basaloid/warty lesions are more common in young women, are very often associated with HPV DNA detection (75-100%), and have a similar risk factor profile as cervical cancer. Keratinising vulvar carcinomas represent the majority of the vulvar lesions (>60%), they occur more often in older women and are more rarely associated with HPV (IARC Monograph Vol 100B).

3.4.2.1 Vulva cancer incidence in Finland

Table 9: Vulva cancer incidence in Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual number of new cancer cases</td>
<td>106</td>
<td>2,227</td>
<td>45,240</td>
</tr>
<tr>
<td>Uncertainty intervals [95% UI]</td>
<td>[71-158]</td>
<td>[2,092-2,371]</td>
<td>[40,656-50,342]</td>
</tr>
<tr>
<td>Crude incidence rate(^b)</td>
<td>3.77</td>
<td>4.14</td>
<td>1.17</td>
</tr>
<tr>
<td>Age-standardized incidence rate(^b)</td>
<td>1.32</td>
<td>1.85</td>
<td>0.85</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old(^a)</td>
<td>0.15</td>
<td>0.20</td>
<td>0.09</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021


\(^a\) Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

\(^b\) Rates per 100,000 women per year.

Data Sources:
Figure 21: Age-specific incidence rates of vulva cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:

Figure 22: Annual number of new cases of vulva cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:
### 3.4.2.2 Vulva cancer mortality in Finland

Table 10: Vulva cancer mortality in Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual number of deaths</td>
<td>37</td>
<td>795</td>
<td>17,427</td>
</tr>
<tr>
<td>Uncertainty intervals [95% UI]</td>
<td>[26-53]</td>
<td>[713-886]</td>
<td>[14,497-20,950]</td>
</tr>
<tr>
<td>Crude mortality rate&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.32</td>
<td>1.48</td>
<td>0.45</td>
</tr>
<tr>
<td>Age-standardized mortality rate&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.34</td>
<td>0.45</td>
<td>0.30</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.03</td>
<td>0.04</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021


<sup>a</sup> Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

<sup>b</sup> Rates per 100,000 women per year.

Data Sources:
Figure 23: Age-specific mortality rates of vulva cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Rates per 100,000 women per year.
Data Sources:

Figure 24: Annual number of deaths of vulva cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Rates per 100,000 women per year.
Data Sources:
3.4.2.3 Vulva cancer incidence and mortality comparison in Finland

Figure 25: Comparison of age-specific vulva cancer incidence and mortality rates in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Rates per 100,000 women per year.

Data Sources

ICO/IARC HPV Information Centre
3.4.3 Vaginal cancer

Cancer of the vagina is a rare cancer, with an estimated 18,000 new cases in 2018, representing 3% of all gynaecologic cancers (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Similar to cervical cancer, the majority of vaginal cancer cases (68%) occur in less developed countries. Most vaginal cancers are squamous cell carcinoma (90%) generally attributable to HPV, followed by clear cell adenocarcinomas and melanoma. Vaginal cancers are primarily reported in developed countries. Metastatic cervical cancer can be misclassified as cancer of the vagina. Invasive vaginal cancer is diagnosed primarily in old women (≥ 65 years) and the diagnosis is rare in women under 45 years whereas the peak incidence of carcinoma in situ is observed between ages 55 and 70 (Vaccine 2008, Vol. 26, Suppl 10).

3.4.3.1 Vaginal cancer incidence in Finland

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual number of new cancer cases</td>
<td>25</td>
<td>450</td>
<td>17,908</td>
</tr>
<tr>
<td>Uncertainty intervals [95% UI]</td>
<td>[16-38]</td>
<td>[390-519]</td>
<td>[14,678-21,848]</td>
</tr>
<tr>
<td>Crude incidence rate(^b)</td>
<td>0.89</td>
<td>0.84</td>
<td>0.46</td>
</tr>
<tr>
<td>Age-standardized incidence rate(^b)</td>
<td>0.31</td>
<td>0.38</td>
<td>0.36</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old(^a)</td>
<td>0.03</td>
<td>0.04</td>
<td>0.04</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/dataSources-methods

\(^a\) Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

\(^b\) Rates per 100,000 women per year.

Data Sources:
Figure 26: Age-specific incidence rates of vaginal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
* Rates per 100,000 women per year.

Data Sources:

Figure 27: Annual number of new cases of vaginal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:

ICO/IARC HPV Information Centre
### 3.4.3.2 Vaginal cancer mortality in Finland

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual number of deaths</td>
<td>13</td>
<td>185</td>
<td>7,995</td>
</tr>
<tr>
<td>Uncertainty intervals [95% UI]</td>
<td>[7-24]</td>
<td>[148-232]</td>
<td>[5,983-10,684]</td>
</tr>
<tr>
<td>Crude mortality rate(^b)</td>
<td>0.46</td>
<td>0.34</td>
<td>0.21</td>
</tr>
<tr>
<td>Age-standardized mortality rate(^b)</td>
<td>0.17</td>
<td>0.13</td>
<td>0.16</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old(^a)</td>
<td>0.02</td>
<td>0.01</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021


\(^a\) Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

\(^b\) Rates per 100,000 women per year.

Data Sources:

Figure 28: Age-specific mortality rates of vaginal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
* Rates per 100,000 women per year.

Data Sources:

Figure 29: Annual number of deaths of vaginal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:
3.4.3.3 Vaginal cancer incidence and mortality comparison in Finland

Figure 30: Comparison of age-specific vaginal cancer incidence and mortality rates in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-source-methods

Rates per 100,000 women per year.

Data Sources:
3.4.4 Penile cancer

The annual burden of penile cancer has been estimated to be 34,000 cases in 2018 worldwide with incidence rates strongly correlating with those of cervical cancer (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Penile cancer is rare and most commonly affects men aged 50-70 years. Incidence rates are higher in less developed countries than in more developed countries, accounting for up to 10% of male cancers in some parts of Africa, South America and Asia. Precursor cancerous penile lesions (PeIN) are rare.

Cancers of the penis are primarily of squamous cell carcinomas (SCC) (95%) and the most common penile SCC histologic sub-types are keratinising (49%), mixed warty-basaloid (17%), verrucous (8%) warty (6%), and basaloid (4%). HPV is most commonly detected in basaloid and warty tumours but is less common in keratinising and verrucous tumours. Approximately 60-100% of PeIN lesions are HPV DNA positive.

3.4.4.1 Penile cancer incidence in Finland

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual number of new cancer cases</td>
<td>40</td>
<td>1,155</td>
<td>36,068</td>
</tr>
<tr>
<td>Uncertainty intervals [95% UI]</td>
<td>[29-56]</td>
<td>[1,056-1,264]</td>
<td>[30,963-42,015]</td>
</tr>
<tr>
<td>Crude incidence rate(^b)</td>
<td>1.46</td>
<td>2.20</td>
<td>0.92</td>
</tr>
<tr>
<td>Age-standardized incidence rate(^b)</td>
<td>0.68</td>
<td>1.11</td>
<td>0.80</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old(^a)</td>
<td>0.08</td>
<td>0.13</td>
<td>0.09</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021


\(^a\) Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

\(^b\) Rates per 100,000 men per year.

Data Sources

Figure 31: Age-specific incidence rates of penile cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
* Rates per 100,000 men per year.

Data Sources:

Figure 32: Annual number of new cases of penile cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:
3.4.4.2 Penile cancer mortality in Finland

Table 14: Penile cancer mortality in Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual number of deaths</td>
<td>10</td>
<td>252</td>
<td>13,211</td>
</tr>
<tr>
<td>Uncertainty intervals [95% UI]</td>
<td>[5-20]</td>
<td>[204-311]</td>
<td>[10,687-16,332]</td>
</tr>
<tr>
<td>Crude mortality rate(^b)</td>
<td>0.37</td>
<td>0.48</td>
<td>0.34</td>
</tr>
<tr>
<td>Age-standardized mortality rate(^b)</td>
<td>0.15</td>
<td>0.21</td>
<td>0.29</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old(^a)</td>
<td>0.02</td>
<td>0.02</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to [http://gco.iarc.fr/today/dataSources-methods](http://gco.iarc.fr/today/dataSources-methods)

\(^a\) Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

\(^b\) Rates per 100,000 men per year.

Data Sources:

Figure 33: Age-specific mortality rates of penile cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
* Rates per 100,000 men per year.

Data Sources:

Figure 34: Annual number of deaths of penile cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

Data Sources:
3.4.4.3 Penile cancer incidence and mortality comparison in Finland

Figure 35: Comparison of age-specific penile cancer incidence and mortality rates in Finland (estimates for 2020)

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Rates per 100,000 men per year.

Data Sources:
3.5 Head and neck cancers

The majority of head and neck cancers are associated with high tobacco and alcohol consumption. However, increasing trends in the incidence at specific sites suggest that other aetiological factors are involved, and infection by certain high-risk types of HPV (i.e. HPV16) have been reported to be associated with head and neck cancers, in particular with oropharyngeal cancer. Current evidence suggests that HPV16 is associated with tonsil cancer (including Waldeyer ring cancer), base of tongue cancer and other oropharyngeal cancer sites. Associations with other head and neck cancer sites such as oral cancer are neither strong nor consistent when compared to molecular-epidemiological data on HPV and oropharyngeal cancer. Association with laryngeal cancer is still unclear (IARC Monograph Vol 100B)

3.5.1 Oropharyngeal cancer

3.5.1.1 Oropharyngeal cancer incidence in Finland

Table 15: Oropharyngeal cancer incidence in Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of new cancer cases</td>
<td>161</td>
<td>3,342</td>
<td>79,045</td>
</tr>
<tr>
<td>Uncertainty intervals of new cancer cases [95% UI]</td>
<td>[124-209]</td>
<td>[3,163-3,531]</td>
<td>[72,769-85,862]</td>
</tr>
<tr>
<td>Crude incidence rate $a^b$</td>
<td>5.89</td>
<td>6.37</td>
<td>2.01</td>
</tr>
<tr>
<td>Age-standardized incidence rate $a^b$</td>
<td>3.15</td>
<td>4.00</td>
<td>1.79</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old$^a$</td>
<td>0.39</td>
<td>0.48</td>
<td>0.22</td>
</tr>
<tr>
<td>WOMEN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of new cancer cases</td>
<td>54</td>
<td>1,090</td>
<td>19,367</td>
</tr>
<tr>
<td>Uncertainty intervals of new cancer cases [95% UI]</td>
<td>[40-72]</td>
<td>[990-1,200]</td>
<td>[16,279-23,041]</td>
</tr>
<tr>
<td>Crude incidence rate $a^c$</td>
<td>1.92</td>
<td>2.03</td>
<td>0.50</td>
</tr>
<tr>
<td>Age-standardized incidence rate $a^c$</td>
<td>0.91</td>
<td>1.21</td>
<td>0.40</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old$^a$</td>
<td>0.11</td>
<td>0.15</td>
<td>0.05</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

$^a$ Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

$^b$ Rates per 100,000 men per year.

$^c$ Rates per 100,000 women per year.

Data Sources

Figure 36: Age-specific incidence rates of oropharyngeal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

Data Sources:

Figure 37: Annual number of new cases of oropharyngeal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

Data Sources:
### 3.5.1.2 Oropharyngeal cancer mortality in Finland

#### Table 16: Oropharyngeal cancer mortality in Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of deaths</td>
<td>29</td>
<td>1,154</td>
<td>39,590</td>
</tr>
<tr>
<td>Uncertainty intervals of mortality cancer cases [95% UI]</td>
<td>[19-44]</td>
<td>[1,056-1,261]</td>
<td>[35,255-44,458]</td>
</tr>
<tr>
<td>Crude mortality rate sa&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.06</td>
<td>2.20</td>
<td>1.01</td>
</tr>
<tr>
<td>Age-standardized mortality rate sa&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.52</td>
<td>1.16</td>
<td>0.89</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.07</td>
<td>0.15</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>WOMEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of deaths</td>
<td>10</td>
<td>328</td>
<td>8,553</td>
</tr>
<tr>
<td>Uncertainty intervals of mortality cancer cases [95% UI]</td>
<td>[5-20]</td>
<td>[279-386]</td>
<td>[6,684-10,945]</td>
</tr>
<tr>
<td>Crude mortality rate sa&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.36</td>
<td>0.61</td>
<td>0.22</td>
</tr>
<tr>
<td>Age-standardized mortality rate sa&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.12</td>
<td>0.30</td>
<td>0.17</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.01</td>
<td>0.04</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021


<sup>a</sup> Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

<sup>b</sup> Rates per 100,000 men per year.

<sup>c</sup> Rates per 100,000 women per year.

Data Sources:

Figure 38: Age-specific mortality rates of oropharyngeal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Rates per 100,000 men per year.
Rates per 100,000 women per year.

Data Sources:

Figure 39: Annual number of deaths of oropharyngeal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:
3.5.1.3 Oropharyngeal cancer incidence and mortality comparison in Finland

Figure 40: Comparison of age-specific oropharyngeal cancer incidence and mortality rates among men in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
* Rates per 100,000 men per year.

Data Sources:

Figure 41: Comparison of age-specific oropharyngeal cancer incidence and mortality rates among women in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
* Rates per 100,000 women per year.

Data Sources:
3.5.2 Oral cavity cancer

3.5.2.1 Oral cavity cancer incidence in Finland

Table 17: Oral cavity cancer incidence in Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of new cancer cases</td>
<td>214</td>
<td>5,582</td>
<td>264,211</td>
</tr>
<tr>
<td>Uncertainty intervals of new cancer cases [95% UI]</td>
<td>[171-268]</td>
<td>[5,372-5,801]</td>
<td>[251,153-277,948]</td>
</tr>
<tr>
<td>Crude incidence rate sa^b</td>
<td>7.83</td>
<td>10.6</td>
<td>6.72</td>
</tr>
<tr>
<td>Age-standardized incidence rate sa^b</td>
<td>3.76</td>
<td>6.01</td>
<td>5.96</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old^a</td>
<td>0.44</td>
<td>0.72</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>WOMEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of new cancer cases</td>
<td>176</td>
<td>3,457</td>
<td>113,502</td>
</tr>
<tr>
<td>Uncertainty intervals of new cancer cases [95% UI]</td>
<td>[142-218]</td>
<td>[3,284-3,640]</td>
<td>[105,599-121,997]</td>
</tr>
<tr>
<td>Crude incidence rate sa^c</td>
<td>6.27</td>
<td>6.43</td>
<td>2.94</td>
</tr>
<tr>
<td>Age-standardized incidence rate sa^c</td>
<td>2.23</td>
<td>3.10</td>
<td>2.28</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old^a</td>
<td>0.26</td>
<td>0.36</td>
<td>0.26</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021


^a Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

^b Rates per 100,000 men per year.

^c Rates per 100,000 women per year.

Data Sources
Figure 42: Age-specific incidence rates of oral cavity cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:

Figure 43: Annual number of new cases of oral cavity cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:
3.5.2.2 Oral cavity cancer incidence and mortality comparison in Finland

Table 18: Oral cavity cancer mortality in Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of deaths</td>
<td>80</td>
<td>1,714</td>
<td>125,022</td>
</tr>
<tr>
<td>Uncertainty intervals of mortality cancer cases [95% UI]</td>
<td>[63-102]</td>
<td>[1,591-1,847]</td>
<td>[116,573-134,084]</td>
</tr>
<tr>
<td>Crude mortality rate sa&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2.93</td>
<td>3.27</td>
<td>3.18</td>
</tr>
<tr>
<td>Age-standardized mortality rate sa&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.24</td>
<td>1.67</td>
<td>3.18</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.15</td>
<td>0.20</td>
<td>0.32</td>
</tr>
<tr>
<td>WOMEN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of deaths</td>
<td>68</td>
<td>1,004</td>
<td>52,735</td>
</tr>
<tr>
<td>Uncertainty intervals of mortality cancer cases [95% UI]</td>
<td>[52-89]</td>
<td>[911-1,107]</td>
<td>[47,690-58,313]</td>
</tr>
<tr>
<td>Crude mortality rate sa&lt;sup&gt;c&lt;/sup&gt;</td>
<td>2.42</td>
<td>1.87</td>
<td>1.36</td>
</tr>
<tr>
<td>Age-standardized mortality rate sa&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.80</td>
<td>0.72</td>
<td>1.04</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.08</td>
<td>0.08</td>
<td>0.12</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021


<sup>a</sup> Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

<sup>b</sup> Rates per 100,000 men per year.

<sup>c</sup> Rates per 100,000 women per year.

Data Sources

Figure 44: Age-specific mortality rates of oral cavity cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:

Figure 45: Annual number of deaths of oral cavity cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:
3.5.2.3 Oral cavity cancer incidence and mortality comparison in Finland

Figure 46: Comparison of age-specific oral cavity cancer incidence and mortality rates among men in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-source-methods

Figure 47: Comparison of age-specific oral cavity cancer incidence and mortality rates among women in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-source-methods
3.5.3 Laryngeal cancer

3.5.3.1 Laryngeal cancer incidence in Finland

Table 19: Laryngeal cancer incidence in Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of new cancer cases</td>
<td>102</td>
<td>3,160</td>
<td>160,265</td>
</tr>
<tr>
<td>Uncertainty intervals of new cancer cases [95% UI]</td>
<td>[76-138]</td>
<td>[2,996-3,334]</td>
<td>[150,633-170,513]</td>
</tr>
<tr>
<td>Crude incidence rate sa(^b)</td>
<td>3.73</td>
<td>6.02</td>
<td>4.08</td>
</tr>
<tr>
<td>Age-standardized incidence rate sa(^b)</td>
<td>1.65</td>
<td>3.16</td>
<td>3.59</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old(^a)</td>
<td>0.22</td>
<td>0.39</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>WOMEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of new cancer cases</td>
<td>15</td>
<td>666</td>
<td>24,350</td>
</tr>
<tr>
<td>Uncertainty intervals of new cancer cases [95% UI]</td>
<td>[8-27]</td>
<td>[594-747]</td>
<td>[20,845-28,444]</td>
</tr>
<tr>
<td>Crude incidence rate sa(^c)</td>
<td>0.53</td>
<td>1.24</td>
<td>0.63</td>
</tr>
<tr>
<td>Age-standardized incidence rate sa(^c)</td>
<td>0.22</td>
<td>0.62</td>
<td>0.49</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old(^a)</td>
<td>0.03</td>
<td>0.08</td>
<td>0.06</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021


\(^a\) Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

\(^b\) Rates per 100,000 men per year.

\(^c\) Rates per 100,000 women per year.

Data Sources:
Figure 48: Age-specific incidence rates of laryngeal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

Data Sources

Figure 49: Annual number of new cases of laryngeal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

Data Sources
### 3.5.3.2 Laryngeal cancer incidence and mortality comparison in Finland

#### Table 20: Laryngeal cancer mortality in Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of deaths</td>
<td>41</td>
<td>1,223</td>
<td>85,351</td>
</tr>
<tr>
<td>Uncertainty intervals of mortality cancer cases [95% UI]</td>
<td>[29-58]</td>
<td>[1,116-1,340]</td>
<td>[78,895-92,335]</td>
</tr>
<tr>
<td>Crude mortality rate sa b</td>
<td>1.50</td>
<td>2.33</td>
<td>2.17</td>
</tr>
<tr>
<td>Age-standardized mortality rate sa b</td>
<td>0.61</td>
<td>1.07</td>
<td>1.89</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old b</td>
<td>0.07</td>
<td>0.13</td>
<td>0.23</td>
</tr>
<tr>
<td><strong>WOMEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual number of deaths</td>
<td>4</td>
<td>251</td>
<td>14,489</td>
</tr>
<tr>
<td>Uncertainty intervals of mortality cancer cases [95% UI]</td>
<td>[2-10]</td>
<td>[208-303]</td>
<td>[11,902-17,639]</td>
</tr>
<tr>
<td>Crude mortality rate sa c</td>
<td>0.14</td>
<td>0.47</td>
<td>0.37</td>
</tr>
<tr>
<td>Age-standardized mortality rate sa c</td>
<td>0.05</td>
<td>0.19</td>
<td>0.28</td>
</tr>
<tr>
<td>Cumulative risk (%) at 75 years old c</td>
<td>0.01</td>
<td>0.02</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021


| a Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.
| b Rates per 100,000 men per year.
| c Rates per 100,000 women per year.

**Data Sources**

Figure 50: Age-specific mortality rates of laryngeal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:

Figure 51: Annual number of deaths of laryngeal cancer in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:
3.5.3.3 Laryngeal cancer incidence and mortality comparison in Finland

Figure 52: Comparison of age-specific laryngeal cancer incidence and mortality rates among men in Finland (estimates for 2020)

- Data accessed on 27 Jan 2021
- For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
- Data Sources:

Figure 53: Comparison of age-specific laryngeal cancer incidence and mortality rates among women in Finland (estimates for 2020)

- Data accessed on 27 Jan 2021
- For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
- Data Sources:
4 HPV related statistics

HPV infection is commonly found in the anogenital tract of men and women with and without clinical lesions. The aetiological role of HPV infection among women with cervical cancer is well-established, and there is growing evidence of its central role in other anogenital sites. HPV is also responsible for other diseases such as recurrent juvenile respiratory papillomatosis and genital warts, both mainly caused by HPV types 6 and 11 (Lacey CJ, Vaccine 2006; 24(S3):35). For this section, the methodologies used to compile the information on HPV burden are derived from systematic reviews and meta-analyses of the literature. Due to the limitations of HPV DNA detection methods and study designs used, these data should be interpreted with caution and used only as a guide to assess the burden of HPV infection within the population. (Vaccine 2006, Vol. 24, Suppl 3; Vaccine 2008, Vol. 26, Suppl 10; Vaccine 2012, Vol. 30, Suppl 5; IARC Monographs 2007, Vol. 90).

4.1 HPV burden in women with normal cervical cytology, cervical precancerous lesions or invasive cervical cancer

The statistics shown in this section focus on HPV infection in the cervix uteri. HPV cervical infection results in cervical morphological lesions ranging from normalcy (cytologically normal women) to different stages of precancerous lesions (CIN-1, CIN-2, CIN-3/CIS) and invasive cervical cancer. HPV infection is measured by HPV DNA detection in cervical cells (fresh tissue, paraffin embedded or exfoliated cells). The prevalence of HPV increases with lesion severity. HPV causes virtually 100% of cervical cancer cases, and an underestimation of HPV prevalence in cervical cancer is most likely due to the limitations of study methodologies. Worldwide, HPV16 and 18 (the two vaccine-preventable types) contribute to over 70% of all cervical cancer cases, between 41% and 67% of high-grade cervical lesions and 16-32% of low-grade cervical lesions. After HPV16/18, the six most common HPV types are the same in all world regions, namely 31, 33, 35, 45, 52 and 58; these account for an additional 20% of cervical cancers worldwide (Clifford G, Vaccine 2006; 24(S3):26).

Methods: Prevalence and type distribution of human papillomavirus in cervical carcinoma, low-grade cervical lesions, high-grade cervical lesions and normal cytology: systematic review and meta-analysis

A systematic review of the literature was conducted regarding the worldwide HPV-prevalence and type distribution for cervical carcinoma, low-grade cervical lesions, high-grade cervical lesions and normal cytology from 1990 to 'data as of' indicated in each section. The search terms for the review were 'HPV' AND cerv* using Pubmed. There were no limits in publication language. References cited in selected articles were also investigated. Inclusion criteria were: HPV DNA detection by means of PCR or HC2, a minimum of 20 cases for cervical carcinoma, 20 cases for low-grade cervical lesions, 20 cases for high-grade cervical lesions and 100 cases for normal cytology and a detailed description of HPV DNA detection and genotyping techniques used. The number of cases tested and HPV positive extracted for each study were pooled to estimate the prevalence of HPV DNA and the HPV type distribution globally and by geographical region. Binomial 95% confidence intervals were calculated for each HPV prevalence. For more details refer to the methods document.
4.1.1 HPV prevalence in women with normal cervical cytology

Figure 54: Crude age-specific HPV prevalence (%) and 95% confidence interval in women with normal cervical cytology in Finland

Data updated on 30 Jun 2015 (data as of 30 Jun 2014)

Data Sources:
Leinonen M, Int J Cancer 2008; 123: 1344
Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until June 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453

Figure 55: HPV prevalence among women with normal cervical cytology in Finland, by study

Data updated on 30 Jun 2015 (data as of 30 Jun 2014)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)
\(^a\) Number of women tested
\(^b\) Women from the general population, including some with cytological cervical abnormalities

Data Sources:
Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until June 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453
4.1.2 HPV type distribution among women with normal cervical cytology, precancerous cervical lesions and cervical cancer

Table 21: Prevalence of HPV16 and HPV18 by cytology in Finland

<table>
<thead>
<tr>
<th>Cytology</th>
<th>No. tested</th>
<th>HPV 16/18 Prevalence % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal cytology</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Low-grade lesions</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>High-grade lesions</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical cancer</td>
<td>460</td>
<td>88.5 (85.2-91.1)</td>
</tr>
</tbody>
</table>

Data updated on 19 May 2017 (data as of 30 Jun 2015 / 30 Nov 2014)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)

Data Sources:
1 Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until November 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453
2 Based on meta-analysis performed by IARC’s Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Clifford GM, Cancer Epidemiol Biomarkers Prev 2005;14:1157
4 Contributing studies: Iwasawa A, Cancer 1996; 77: 2275

Figure 56: HPV 16 prevalence among women with normal cervical cytology in Finland, by study

Study | N | Study
--- | --- | ---
No data available

Data updated on 30 Jun 2015 (data as of 30 Jun 2014)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)

Data Sources:
Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until June 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453
Figure 57: HPV 16 prevalence among women with low-grade cervical lesions in Finland, by study

Data updated on 27 Jan 2017 (data as of 30 Jun 2015)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)

Data Sources:
Based on meta-analysis performed by IARC’s Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Clifford GM, Cancer Epidemiol Biomarkers Prev 2005;14:1157

Figure 58: HPV 16 prevalence among women with high-grade cervical lesions in Finland, by study

Data updated on 27 Jan 2017 (data as of 30 Jun 2015)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)

Data Sources:
Figure 59: HPV 16 prevalence among women with invasive cervical cancer in Finland, by study

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>% (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iwasawa 1996</td>
<td>460</td>
<td>63.5 (59.0−67.7)</td>
</tr>
</tbody>
</table>

Data updated on 19 May 2017 (data as of 30 Jun 2015)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)

* Number of women tested

Data Sources:
Iwasawa A, Cancer 1996; 77: 2275

Figure 60: Comparison of the ten most frequent HPV oncogenic types in Finland among women with and without cervical lesions

No data available
Figure 61: Comparison of the ten most frequent HPV oncogenic types in Finland among women with invasive cervical cancer by histology

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

1 No data available. No more types than shown were tested or were positive
Table 22: Type-specific HPV prevalence in women with normal cervical cytology, precancerous cervical lesions and invasive cervical cancer in Finland

<table>
<thead>
<tr>
<th>HPV Type</th>
<th>No. tested</th>
<th>Normal cytology</th>
<th>HPV Prev % (95% CI)</th>
<th>No. tested</th>
<th>Low-grade lesions</th>
<th>HPV Prev % (95% CI)</th>
<th>No. tested</th>
<th>High-grade lesions</th>
<th>HPV Prev % (95% CI)</th>
<th>No. tested</th>
<th>Cervical cancer</th>
<th>HPV Prev % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ONCOGENIC HPV TYPES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High-risk HPV types</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>18</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>31</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>33</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>35</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>39</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>45</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>51</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>52</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>56</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>58</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>59</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Probable/possible carcinogen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>30</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>34</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>53</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>66</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>67</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>68</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>69</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>70</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>73</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>82</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>85</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>97</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>NON-ONCOGENIC HPV TYPES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>11</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>32</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>40</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>42</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>43</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>44</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>54</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>55</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>57</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>61</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>62</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>64</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>71</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>72</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>74</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>81</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>83</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>84</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>86</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>87</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>89</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>90</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>91</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Data updated on 30 Jun 2015 (data as of 30 Jun 2015 / 30 Nov 2014)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)

1 Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until November 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453


4 Contributing studies: Iwasawa A, Cancer 1996; 77: 2275


ICO/IARC HPV Information Centre
Table 23: Type-specific HPV prevalence among invasive cervical cancer cases in Finland by histology

<table>
<thead>
<tr>
<th>HPV Type</th>
<th>Any Histology</th>
<th>Squamous cell carcinoma</th>
<th>Adenocarcinoma</th>
<th>Unspecified</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. tested</td>
<td>HPV Prev % (95% CI)</td>
<td>No. tested</td>
<td>HPV Prev % (95% CI)</td>
</tr>
<tr>
<td>ONCOGENIC HPV TYPES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High-risk HPV types</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>460</td>
<td>63.5 (59.0-67.7)</td>
<td>352</td>
<td>77.8 (73.2-81.9)</td>
</tr>
<tr>
<td>18</td>
<td>460</td>
<td>25.0 (21.3-29.2)</td>
<td>352</td>
<td>15.6 (12.2-19.8)</td>
</tr>
<tr>
<td>31</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>33</td>
<td>460</td>
<td>2.6 (1.5-4.5)</td>
<td>352</td>
<td>2.3 (1.2-4.4)</td>
</tr>
<tr>
<td>35</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>39</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>45</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>51</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>52</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>56</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>58</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>59</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Probable/possible carcinogen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>30</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>34</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>35</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>66</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>67</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>68</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>69</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>70</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>73</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>82</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>85</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>97</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>NON-ONCOGENIC HPV TYPES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>11</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>32</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>40</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>42</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>43</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>44</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>54</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>55</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>57</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>61</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>62</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>64</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>71</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>72</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>74</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>81</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>83</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>84</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>86</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>87</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>89</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>90</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>91</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Data updated on 19 May 2017 (data as of 30-Jun 2015)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)

a Number of women tested
b 95% Confidence Interval

Data Sources:
Contributing studies: Iwasawa A. Cancer 1996; 77: 2275
### 4.1.3 HPV type distribution among HIV+ women with normal cervical cytology

Table 24: Studies on HPV prevalence among HIV+ women with normal cytology in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>HPV detection method and targeted HPV types</th>
<th>No. Tested(^a)</th>
<th>HPV Prevalence % (95% CI)(^b)</th>
<th>Prevalence of 5 most frequent HPVs, HPV type (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data updated on 31 Dec 2011 (data as of 31 Dec 2011)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; PCR: Polymerase Chain Reaction; TS: Type Specific

\(^a\) Number of women tested

\(^b\) 95% Confidence Interval

Data Sources:

Systematic review and meta-analysis were performed by the ICO HPV Information Centre up to December 2011. Selected studies had to include at least 20 HIV positive women who had both normal cervical cytology and HPV test results (PCR or HC2).
4.1.4 Terminology

Cytologically normal women
No abnormal cells are observed on the surface of their cervix upon cytology.

Cervical Intraepithelial Neoplasia (CIN) / Squamous Intraepithelial Lesions (SIL)
SIL and CIN are two commonly used terms to describe precancerous lesions or the abnormal growth of squamous cells observed in the cervix. SIL is an abnormal result derived from cervical cytological screening or Pap smear testing. CIN is a histological diagnosis made upon analysis of cervical tissue obtained by biopsy or surgical excision. The condition is graded as CIN 1, 2 or 3, according to the thickness of the abnormal epithelium (1/3, 2/3 or the entire thickness).

Low-grade cervical lesions (LSIL/CIN-1)
Low-grade cervical lesions are defined by early changes in size, shape, and number of abnormal cells formed on the surface of the cervix and may be referred to as mild dysplasia, LSIL, or CIN-1.

High-grade cervical lesions (HSIL/ CIN-2 / CIN-3 / CIS)
High-grade cervical lesions are defined by a large number of precancerous cells on the surface of the cervix that are distinctly different from normal cells. They have the potential to become cancerous cells and invade deeper tissues of the cervix. These lesions may be referred to as moderate or severe dysplasia, HSIL, CIN-2, CIN-3 or cervical carcinoma in situ (CIS).

Carcinoma in situ (CIS)
Preinvasive malignancy limited to the epithelium without invasion of the basement membrane. CIN 3 encompasses the squamous carcinoma in situ.

Invasive cervical cancer (ICC) / Cervical cancer
If the high-grade precancerous cells invade the basement membrane is called ICC. ICC stages range from stage I (cancer is in the cervix or uterus only) to stage IV (the cancer has spread to distant organs, such as the liver).

Invasive squamous cell carcinoma
Invasive carcinoma composed of cells resembling those of squamous epithelium.

Adenocarcinoma
Invasive tumour with glandular and squamous elements intermingled.
4.2 HPV burden in anogenital cancers other than cervix

Methods: Prevalence and type distribution of human papillomavirus in carcinoma of the vulva, vagina, anus and penis: systematic review and meta-analysis

A systematic review of the literature was conducted on the worldwide HPV-prevalence and type distribution for anogenital carcinomas other than cervix from January 1986 to 'data as of' indicated in each section. The search terms for the review were 'HPV' AND (anus OR anal) OR (penile) OR vagin* OR vulv* using Pubmed. There were no limits in publication language. References cited in selected articles were also investigated. Inclusion criteria were: HPV DNA detection by means of PCR, a minimum of 10 cases by lesion and a detailed description of HPV DNA detection and genotyping techniques used. The number of cases tested and HPV positive cases were extracted for each study to estimate the prevalence of HPV DNA and the HPV type distribution. Binomial 95% confidence intervals were calculated for each HPV prevalence.
4.2.1 Anal cancer and precancerous anal lesions

Anal cancer is similar to cervical cancer with respect to overall HPV DNA positivity, with approximately 100% of anal squamous cell carcinoma cases associated with HPV infection worldwide (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). HPV16 is the most common type detected, representing 73% of all HPV-positive tumours. HPV18 is the second most common type detected and is found in approximately 5% of cases. HPV DNA is also detected in the majority of precancerous anal lesions (AIN) (91.5% in AIN1 and 93.9% in AIN2/3) (De Vuyst H et al. Int J Cancer 2009; 124: 1626-36). In this section, the burden of HPV among cases of anal cancers and precancerous anal lesions in Finland are presented.

Table 25: Studies on HPV prevalence among anal cancer cases in Finland (male and female)

<table>
<thead>
<tr>
<th>Study</th>
<th>HPV detection method and targeted HPV types</th>
<th>No. Tested</th>
<th>HPV Prevalence % (95% CI)a</th>
<th>Prevalence of 5 most frequent HPVs, HPV type (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No data available</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;

a 95% Confidence Interval

Data Sources:

Table 26: Studies on HPV prevalence among cases of AIN2/3 in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>HPV detection method and targeted HPV types</th>
<th>No. Tested</th>
<th>HPV Prevalence % (95% CI)a</th>
<th>Prevalence of 5 most frequent HPVs, HPV type (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No data available</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;

AIN 2/3: Anal intraepithelial neoplasia of grade 2/3

a 95% Confidence Interval

Data Sources:
Figure 62: Comparison of the ten most frequent HPV types in anal cancer cases in Europe and the World

<table>
<thead>
<tr>
<th>Type</th>
<th>Europe (a)</th>
<th>World (b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>2.3</td>
<td>2.3</td>
</tr>
<tr>
<td>11</td>
<td>7.0</td>
<td>7.0</td>
</tr>
<tr>
<td>33</td>
<td>3.6</td>
<td>3.6</td>
</tr>
<tr>
<td>56</td>
<td>4.7</td>
<td>4.7</td>
</tr>
<tr>
<td>74</td>
<td>4.7</td>
<td>4.7</td>
</tr>
<tr>
<td>45</td>
<td>5.3</td>
<td>5.3</td>
</tr>
<tr>
<td>35</td>
<td>3.0</td>
<td>3.0</td>
</tr>
<tr>
<td>37</td>
<td>4.7</td>
<td>4.7</td>
</tr>
<tr>
<td>33</td>
<td>4.7</td>
<td>4.7</td>
</tr>
<tr>
<td>11</td>
<td>5.3</td>
<td>5.3</td>
</tr>
</tbody>
</table>

Data updated on 9 Feb 2017 (data as of 30 Jun 2014)

a Includes cases from Bosnia-Herzegovina, Czech Republic, France, Germany, Poland, Portugal, Slovenia, Spain and United Kingdom
b Includes cases from Europe (Bosnia-Herzegovina, Czech Republic, France, Germany, Poland, Portugal, Slovenia, Spain and United Kingdom); America (Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay and United States); Africa (Mali, Nigeria and Senegal); Asia (Bangladesh, India and South Korea)

Data Sources:
Data from Alemany L, Int J Cancer 2015; 136: 98. This study has gathered the largest international series of anal cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

Figure 63: Comparison of the ten most frequent HPV types in AIN 2/3 cases in Europe and the World

<table>
<thead>
<tr>
<th>Type</th>
<th>Europe (a)</th>
<th>World (b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>4.3</td>
<td>4.3</td>
</tr>
<tr>
<td>11</td>
<td>6.0</td>
<td>6.0</td>
</tr>
<tr>
<td>33</td>
<td>8.7</td>
<td>8.7</td>
</tr>
<tr>
<td>56</td>
<td>8.7</td>
<td>8.7</td>
</tr>
<tr>
<td>74</td>
<td>8.7</td>
<td>8.7</td>
</tr>
<tr>
<td>45</td>
<td>4.3</td>
<td>4.3</td>
</tr>
<tr>
<td>35</td>
<td>4.3</td>
<td>4.3</td>
</tr>
<tr>
<td>33</td>
<td>4.3</td>
<td>4.3</td>
</tr>
<tr>
<td>11</td>
<td>3.0</td>
<td>3.0</td>
</tr>
<tr>
<td>6</td>
<td>1.2</td>
<td>1.2</td>
</tr>
</tbody>
</table>

Data updated on 7 Feb 2017 (data as of 30 Jun 2014)

AIN 2/3: Anal intraepithelial neoplasia of grade 2/3
a Includes cases from Bosnia-Herzegovina, Czech Republic, France, Germany, Poland, Portugal, Slovenia, Spain and United Kingdom
b Includes cases from Europe (Bosnia-Herzegovina, Czech Republic, France, Germany, Poland, Portugal, Slovenia, Spain and United Kingdom); America (Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay)

Data Sources:
Data from Alemany L, Int J Cancer 2015; 136: 98. This study has gathered the largest international series of anal cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.
### 4.2.2 Vulvar cancer and precancerous vulvar lesions

HPV attribution for vulvar cancer is 48% among age 15-54 years, 28% among age 55-64 years, and 15% among age 65+ worldwide (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Vulvar cancer has two distinct histological patterns with two different risk factor profiles: (1) basaloid/warty types (2) keratinising types. Basaloid/warty lesions are more common in young women, are frequently found adjacent to VIN, are very often associated with HPV DNA detection (86%), and have a similar risk factor profile as cervical cancer. Keratinising vulvar carcinomas represent the majority of the vulvar lesions (>60%). These lesions develop from non HPV-related chronic vulvar dermatoses, especially lichen sclerosus and/or squamous hyperplasia, their immediate cancer precursor lesion is differentiated VIN, they occur more often in older women, and are rarely associated with HPV (6%) or with any of the other risk factors typical of cervical cancer. HPV prevalence is frequently detected among cases of high-grade VIN (VIN2/3) (85.3%). HPV 16 is the most common type detected followed by HPV 33 (De Vuyst H et al. Int J Cancer 2009; 124: 1626-36). In this section, the HPV burden among cases of vulvar cancer cases and precancerous vulvar lesions in Finland are presented.

#### Table 27: Studies on HPV prevalence among vulvar cancer cases in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>HPV detection method and targeted HPV types</th>
<th>No. Tested</th>
<th>% (95% CI) ^a</th>
<th>Prevalence of 5 most frequent HPVs, HPV type (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iwasawa 1997</td>
<td>PCR-MY09/11, PCR L1-Consensus primer, PCR-E6, TS (HPV 6, 11, 16, 18, 33)</td>
<td>74</td>
<td>36.5 (26.4-47.9)</td>
<td>HPV 16 (25.7), HPV 18 (12.2), HPV 33 (1.4)</td>
</tr>
</tbody>
</table>

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;

^a 95% Confidence Interval

Data Sources:
Iwasawa A, Obstet Gynecol 1997; 89: 81


#### Table 28: Studies on HPV prevalence among VIN 2/3 cases in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>HPV detection method and targeted HPV types</th>
<th>No. Tested</th>
<th>% (95% CI) ^a</th>
<th>Prevalence of 5 most frequent HPVs, HPV type (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No data available</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;

^a 95% Confidence Interval

Data Sources:
Figure 64: Comparison of the ten most frequent HPV types in cases of vulvar cancer in Europe and the World

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

* Includes cases from Austria, Belarus, Bosnia-Herzegovina, Czech Republic, France, Germany, Greece, Italy, Poland, Portugal, Spain and United Kingdom.

† Includes cases from America (Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Uruguay, United States of America and Venezuela); Africa (Mali, Mozambique, Nigeria, and Senegal); Oceania (Australia and New Zealand); Europe (Austria, Belarus, Bosnia-Herzegovina, Czech Republic, France, Germany, Greece, Italy, Poland, Portugal, Spain and United Kingdom); and in Asia (Bangladesh, India, Israel, South Korea, Kuwait, Lebanon, Philippines, Taiwan and Turkey)

Data Sources: Data from de Sanjosé S, Eur J Cancer 2013; 49: 3450. This study has gathered the largest international series of vulva cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

Figure 65: Comparison of the ten most frequent HPV types in VIN 2/3 cases in Europe and the World

Data updated on 30 Jun 2014 (data as of 30 Jun 2014)

VIN 2/3: Vulvar intraepithelial neoplasia of grade 2/3

* Includes cases from Austria, Belarus, Bosnia-Herzegovina, Czech Republic, France, Germany, Greece, Italy, Poland, Portugal, Spain and United Kingdom.

† Includes cases from America (Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Uruguay and Venezuela); Oceania (Australia and New Zealand); Europe (Austria, Belarus, Bosnia-Herzegovina, Czech Republic, France, Germany, Greece, Italy, Poland, Portugal, Spain and United Kingdom); and in Asia (Bangladesh, India, Israel, South Korea, Kuwait, Lebanon, Philippines, Taiwan and Turkey)

Data Sources: Data from de Sanjosé S, Eur J Cancer 2013; 49: 3450. This study has gathered the largest international series of vulva cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.
### 4.2.3 Vaginal cancer and precancerous vaginal lesions

Vaginal and cervical cancers share similar risk factors and it is generally accepted that both carcinomas share the same aetiology of HPV infection although there is limited evidence available. Women with vaginal cancer are more likely to have a history of other ano-genital cancers, particularly of the cervix, and these two carcinomas are frequently diagnosed simultaneously. HPV DNA is detected among 78% of invasive vaginal carcinomas and 91% of high-grade vaginal neoplasias (VaIN2/3). HPV16 is the most common type in high-grade vaginal neoplasias and it is detected in at least 78% of HPV-positive carcinomas (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190; De Vuyst H et al. Int J Cancer 2009; 124:1626-36). In this section, the HPV burden among cases of vaginal cancer cases and precancerous vaginal lesions in Finland are presented.

#### Table 29: Studies on HPV prevalence among vaginal cancer cases in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>HPV detection method and targeted HPV types</th>
<th>No. Tested</th>
<th>HPV Prevalence % (95% CI)a</th>
<th>Prevalence of 5 most frequent HPVs, HPV type (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No data available</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*Data updated on 30 Jun 2015 (data as of 30 Jun 2015)*

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;

*95% Confidence Interval

**Data Sources:**

#### Table 30: Studies on HPV prevalence among VaIN 2/3 cases in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>HPV detection method and targeted HPV types</th>
<th>No. Tested</th>
<th>HPV Prevalence % (95% CI)a</th>
<th>Prevalence of 5 most frequent HPVs, HPV type (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No data available</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*Data updated on 30 Jun 2015 (data as of 30 Jun 2015)*

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;

**Data Sources:**

ICO/IARC HPV Information Centre
Figure 66: Comparison of the ten most frequent HPV types in cases of vaginal cancer in Europe and the World

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

* Includes cases from Austria, Belarus, Czech Republic, France, Germany, Greece, Poland, Spain and United Kingdom.

b Includes cases from Europe (Austria, Belarus, Czech Republic, France, Germany, Greece, Poland, Spain and United Kingdom); America (Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Mexico, Paraguay, Uruguay, United states of America and Venezuela); Africa (Mozambique, Nigeria); Asia (Bangladesh, India, Israel, South Korea, Kuwait, Philippines, Taiwan and Turkey); and Oceania (Australia).

Data Sources:
Data from Alemany L, Eur J Cancer 2014; 50: 2846. This study has gathered the largest international series of vaginal cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

Figure 67: Comparison of the ten most frequent HPV types in VaIN 2/3 cases in Europe and the World

Data updated on 30 Jun 2014 (data as of 30 Jun 2014)

* Includes cases from Austria, Belarus, Czech Republic, France, Germany, Greece, Poland, Spain and United Kingdom.

b Includes cases from Europe (Austria, Belarus, Czech Republic, France, Germany, Greece, Poland, Spain and United Kingdom); America (Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Mexico, Paraguay, Uruguay, United states of America and Venezuela); Asia (Bangladesh, India, Israel, South Korea, Kuwait, Philippines, Taiwan and Turkey); and Oceania (Australia).

Data Sources:
Data from Alemany L, Eur J Cancer 2014; 50: 2846. This study has gathered the largest international series of vaginal cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.
4.2.4 Penile cancer and precancerous penile lesions

HPV DNA is detectable in approximately 51% of all penile cancers (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Among HPV-related penile tumours, HPV16 is the most common type detected, followed by HPV18 and HPV types 6/11 (Miralles C et al. J Clin Pathol 2009;62:870-8). Over 95% of invasive penile cancers are SCC and the most common penile SCC histologic sub-types are keratinising (49%), mixed warty-basaloid (17%), verrucous (8%), warty (6%), and basaloid (4%). HPV is commonly detected in basaloid and warty tumours but is less common in keratinising and verrucous tumours. In this section, the HPV burden among cases of penile cancer cases and precancerous penile lesions in Finland are presented.

Table 31: Studies on HPV prevalence among penile cancer cases in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>HPV detection method and targeted HPV types</th>
<th>No. Tested</th>
<th>% (95% CI)</th>
<th>Prevalence of 5 most frequent HPVs, HPV type (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No data available</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Data updated on 5 Mar 2015 (data as of 30 Jun 2014)

Table 32: Studies on HPV prevalence among PeIN 2/3 cases in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>HPV detection method and targeted HPV types</th>
<th>No. Tested</th>
<th>% (95% CI)</th>
<th>Prevalence of 5 most frequent HPVs, HPV type (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No data available</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Data updated on 10 Feb 2015 (data as of 30 Jun 2014)
Figure 68: Comparison of the ten most frequent HPV types in cases of penile cancer in Europe and the World

![Graph showing comparison of HPV types in penile cancer cases between Europe and the World.]

**Data updated on 9 Feb 2017 (data as of 30 Jun 2015)**

- **Europe (a)**: Includes cases from Czech Republic, France, Greece, Poland, Portugal, Spain and United Kingdom.
- **World (b)**: Includes cases from Australia, Bangladesh, India, South Korea, Lebanon, Philippines, Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Venezuela and United States, Mozambique, Nigeria, Senegal, Czech Republic, France, Greece, Poland, Portugal, Spain and United Kingdom.

**Data Sources**

Figure 69: Comparison of the ten most frequent HPV types in PeIN 2/3 cases in Europe and the World

![Graph showing comparison of HPV types in PeIN 2/3 cases between Europe and the World.]

**Data updated on 9 Feb 2017 (data as of 30 Jun 2015)**

- **Europe (a)**: Includes cases from Czech Republic, France, Greece, Poland, Portugal, Spain and United Kingdom.
- **World (b)**: Includes cases from Australia, Bangladesh, India, South Korea, Lebanon, Philippines, Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Venezuela, Mozambique, Nigeria, Senegal, Czech Republic, France, Greece, Poland, Portugal, Spain and United Kingdom.

**Data Sources**

Based on systematic reviews and meta-analysis performed by ICO. Reference publications: 1) Ndiaye C, Lancet Oncol 2014, 15: 1319 2) Kreimer AR, Cancer Epidemiol Biomarkers Prev 2005, 14: 467

ICO/IARC HPV Information Centre
4.3 HPV burden in men

The information to date regarding anogenital HPV infection is primarily derived from cross-sectional studies of selected populations such as general population, university students, military recruits, and studies that examined husbands of control women, as well as from prospective studies. Special subgroups include mainly studies that examined STD (sexually transmitted diseases) clinic attendees, MSM (men who have sex with men), HIV positive men, and partners of women with HPV lesions, CIN (cervical intraepithelial neoplasia), cervical cancer or cervical carcinoma in situ. Globally, prevalence of external genital HPV infection in men is higher than cervical HPV infection in women, but persistence is less likely. As with genital HPV prevalence, high numbers of sexual partners increase the acquisition of oncogenic HPV infections (Vaccine 2012, Vol. 30, Suppl 5). In this section, the HPV burden among men in Finland is presented.

Methods

HPV burden in men was based on published systematic reviews and meta-analyses (Dunne EF, J Infect Dis 2006; 194: 1044, Smith JS, J Adolesc Health 2011; 48: 540, Olesen TB, Sex Transm Infect 2014; 90: 455, and Hebnes JB, J Sex Med 2014; 11: 2630) up to October 31, 2015. The search terms for the review were human papillomavirus, men, polymerase chain reaction (PCR), hybrid capture (HC), and viral DNA. References cited in selected articles were also investigated. Inclusion criteria were: HPV DNA detection by means of PCR or HC (ISH if data are not available for the country), and a detailed description of HPV DNA detection and genotyping techniques used. The number of cases tested and HPV positive cases were extracted for each study to estimate the anogenital prevalence of HPV DNA. Binomial 95% confidence intervals were calculated for each anogenital HPV prevalence.

Table 33: Studies on HPV prevalence among men in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>Anatomic sites samples</th>
<th>HPV detection method</th>
<th>Population</th>
<th>Age (years)</th>
<th>No. Tested</th>
<th>HPV Prevalence (% (95% CI))a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hippeläinen 1993</td>
<td>Glans, prepuce, corona sulcus, urethral meatus</td>
<td>PCR-MY09/11 TS 6,11,16,18,31,33</td>
<td>Voluntary conscripts Mean 20</td>
<td>285</td>
<td>16.5</td>
<td>(12.4-21.3)</td>
</tr>
<tr>
<td>Kero 2011</td>
<td>Urethra</td>
<td>PCR-MY09/11 and GP5+/6+</td>
<td>Sexual partners of pregnant women 19-46</td>
<td>128</td>
<td>22.7</td>
<td>(15.7-30.9)</td>
</tr>
</tbody>
</table>

Data updated on 31 Oct 2015 (data as of 31 Oct 2015)

Table 34: Studies on HPV prevalence among men from special subgroups in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>Anatomic sites samples</th>
<th>HPV detection method</th>
<th>Population</th>
<th>Age (years)</th>
<th>No. Tested</th>
<th>HPV Prevalence (% (95% CI))a</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

Data updated on 31 Oct 2015 (data as of 31 Oct 2015)
4.4 HPV burden in the head and neck

The last evaluation of the International Agency for Research in Cancer (IARC) on the carcinogenicity of HPV in humans concluded that (a) there is enough evidence for the carcinogenicity of HPV type 16 in the oral cavity, oropharynx (including tonsil cancer, base of tongue cancer and other oropharyngeal cancer sites), and (b) limited evidence for laryngeal cancer (IARC Monograph Vol 100B). There is increasing evidence that HPV-related oropharyngeal cancers constitute an epidemiological, molecular and clinical distinct form as compared to non HPV-related ones. Some studies indicate that the most likely explanation for the origin of this distinct form of head and neck cancers associated with HPV is a sexually acquired oral HPV infection that is not cleared, persists and evolves into a neoplastic lesion. Around 30% of oropharyngeal cancers (which mainly comprises the tonsils and base of tongue sites) are caused by HPV with HPV16 being the most frequent type (de Martel C et al. Int J Cancer 2017;141(4):664-670). Attributable fraction varies greatly worldwide, being highest in more developed countries (60% in Republic of Korea, 51% in North America, 50% in Eastern Europe, 46% in Japan, 42% in North-Western Europe, 41% in Australia/New Zealand, 24% in South Europe, 23% in China, 22% in India, and 13% in elsewhere) (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). In this section, the HPV burden in the head and neck in Finland is presented.

4.4.1 Burden of oral HPV infection in healthy population

Table 35: Studies on oral HPV prevalence among healthy in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>Specimen collection method / anatomic site</th>
<th>HPV detection method</th>
<th>Population</th>
<th>% males</th>
<th>Age (years)b</th>
<th>No. testedc</th>
<th>HPV prevalence % (95% CI)</th>
<th>High-Risk HPV prevalence % (95% CI)</th>
<th>5 most frequent HPV, HPV type (n)d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leimola-Virtanen 1996</td>
<td>Brush/swab / Most parts of mouth</td>
<td>PCR- GP5/6</td>
<td>Convenient samples from general population</td>
<td>0</td>
<td>55</td>
<td>131</td>
<td>10.7 (6.5-17.1)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Kero 2012</td>
<td>Brush/swab / Most parts of mouth</td>
<td>PCR- GP5+6+MY09/11</td>
<td>Convenient samples from general population</td>
<td>100</td>
<td>19-46</td>
<td>131</td>
<td>18.3 (12.6-25.8)</td>
<td>13 (8.3-19.8)</td>
<td>HPV16 (12); 33 (3); 82 (3); 6 (1); 11 (1); 18 (1); 31 (1); 43 (1); 70 (1)</td>
</tr>
</tbody>
</table>

Data updated on 19 Oct 2021 (data as of 19 May 2015)

- 95% CI: 95% Confidence Interval
- TS: type-specific; RT-PCR: real-time PCR; qPCR: quantitative PCR
- NS: not specified
- number of cases tested for HPV DNA
- number of cases positive for the specific HPV-type

Data Sources:
Systematic review and meta-analysis was performed by ICO HPV Information Centre until May 19, 2015. Reference publication: Mena M et al. J Infect Dis 2019;219(10):1574-1585.
4.4.2 HPV burden in head and neck cancers

Table 36: Studies on HPV prevalence among cases of oral cavity cancer in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>HPV detection method and targeted HPV types</th>
<th>No. Tested</th>
<th>%</th>
<th>(95% CI)&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Prevalence of 5 most frequent HPVs, HPV type (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No data available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WOMEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No data available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOTH OR UNSPECIFIED</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Koskinen 2003</td>
<td>SPF10 (L1) LiPA 25</td>
<td>28</td>
<td>64.3</td>
<td>(45.8-79.3)</td>
<td>HPV 16 (46.4) HPV 33 (21.4)</td>
</tr>
<tr>
<td>Mork 2001&lt;sup&gt;b&lt;/sup&gt;</td>
<td>GP5+/GP6+ (L1) and CPI/CPII (L1) Amplification with TS primers (6. 11. 16. 18. 33)</td>
<td>91</td>
<td>7.7</td>
<td>(3.8-15.0)</td>
<td>HPV 16 (4.4) HPV 11 (1.1) HPV 33 (1.1) HPV 6 (1.1)</td>
</tr>
</tbody>
</table>

Data updated on 9 May 2016 (data as of 31 Dec 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific.

Only for European countries

<sup>a</sup> 95% Confidence Interval

<sup>b</sup> Includes cases from Norway, Sweden and Finland


Table 37: Studies on HPV prevalence among cases of oropharyngeal cancer in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>HPV detection method and targeted HPV types</th>
<th>No. Tested</th>
<th>%</th>
<th>(95% CI)&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Prevalence of 5 most frequent HPVs, HPV type (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No data available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WOMEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No data available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOTH OR UNSPECIFIED</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No data available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data updated on 9 May 2016 (data as of 31 Dec 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific.

Only for European countries

<sup>a</sup> 95% Confidence Interval

Data Sources: Based on systematic reviews and meta-analysis performed by ICO. Reference publications: 1) Ndiaye C, Lancet Oncol 2014; 15: 1319 2) Kreimer AR, Cancer Epidemiol Biomarkers Prev 2005; 14: 467

Table 38: Studies on HPV prevalence among cases of hypopharyngeal or laryngeal cancer in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>HPV detection method and targeted HPV types</th>
<th>No. Tested</th>
<th>%</th>
<th>(95% CI)&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Prevalence of 5 most frequent HPVs, HPV type (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No data available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WOMEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No data available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOTH OR UNSPECIFIED</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Koskinen 2003</td>
<td>SPF10 (L1) LiPA 25</td>
<td>28</td>
<td>50.0</td>
<td>(32.6-67.4)</td>
<td>HPV 16 (46.4) HPV 33 (14.3)</td>
</tr>
<tr>
<td>Koskinen 2007&lt;sup&gt;b&lt;/sup&gt;</td>
<td>MY09/MY11 (L1). GPS5+/GP6+ (L1) and SPF10 (L1) LiPA 25</td>
<td>69</td>
<td>4.3</td>
<td>(1.5-12.0)</td>
<td>HPV 16 (1.4)</td>
</tr>
<tr>
<td>Mork 2001&lt;sup&gt;b&lt;/sup&gt;</td>
<td>GP5+/GP6+ (L1) and CPI/CPII (L1) Amplification with TS primers (6. 11. 16. 18. 33)</td>
<td>40</td>
<td>2.5</td>
<td>(0.4-12.9)</td>
<td>HPV 16 (2.5)</td>
</tr>
</tbody>
</table>

Data updated on 9 May 2016 (data as of 31 Dec 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific.

Only for European countries

<sup>a</sup> 95% Confidence Interval

<sup>b</sup> Includes cases from Norway, Sweden and Finland

Data Sources: Based on systematic reviews and meta-analysis performed by ICO. Reference publications: 1) Ndiaye C, Lancet Oncol 2014; 15: 1319 2) Kreimer AR, Cancer Epidemiol Biomarkers Prev 2005; 14: 467

ICO/IARC HPV Information Centre
5 Factors contributing to cervical cancer

HPV is a necessary cause of cervical cancer, but it is not a sufficient cause. Other cofactors are necessary for progression from cervical HPV infection to cancer. Tobacco smoking, high parity, long-term hormonal contraceptive use, and co-infection with HIV have been identified as established cofactors. Co-infection with Chlamydia trachomatis and herpes simplex virus type-2, immunosuppression, and certain dietary deficiencies are other probable cofactors. Genetic and immunological host factors and viral factors other than type, such as variants of type, viral load and viral integration, are likely to be important but have not been clearly identified. (Muñoz N, Vaccine 2006; 24(S3): 1-10). In this section, the prevalence of smoking, parity (fertility), oral contraceptive use, and HIV in Finland are presented.

Table 39: Factors contributing to cervical carcinogenesis (cofactors) in Finland

<table>
<thead>
<tr>
<th>INDICATOR</th>
<th>MALE</th>
<th>FEMALE</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking of any tobacco adjusted prevalence (%)</td>
<td>Current&lt;sup&gt;a&lt;/sup&gt; 21.1 [18.6-25.5]</td>
<td>15.3 [12.2-18.3]</td>
<td>18.2 [14.4-21.8]</td>
</tr>
<tr>
<td>Cigarette smoking adjusted prevalence (%)</td>
<td>Current&lt;sup&gt;c&lt;/sup&gt; 21.1 [18.6-25.5]</td>
<td>15.3 [12.2-18.3]</td>
<td>18.2 [14.4-21.8]</td>
</tr>
<tr>
<td>Parity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total fertility rate per woman</td>
<td>-</td>
<td>1.8</td>
<td>-</td>
</tr>
<tr>
<td>15-19 yrs</td>
<td>-</td>
<td>4.9</td>
<td>-</td>
</tr>
<tr>
<td>20-24 yrs</td>
<td>-</td>
<td>39.4</td>
<td>-</td>
</tr>
<tr>
<td>25-29 yrs</td>
<td>-</td>
<td>86.3</td>
<td>-</td>
</tr>
<tr>
<td>30-34 yrs</td>
<td>-</td>
<td>99.8</td>
<td>-</td>
</tr>
<tr>
<td>35-39 yrs</td>
<td>-</td>
<td>54.0</td>
<td>-</td>
</tr>
<tr>
<td>40-44 yrs</td>
<td>-</td>
<td>13.3</td>
<td>-</td>
</tr>
<tr>
<td>45-49 yrs</td>
<td>-</td>
<td>0.8</td>
<td>-</td>
</tr>
<tr>
<td>Age-specific fertility rate (per 1000 women)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV prevalence (%) among sex workers</td>
<td>-</td>
<td>-</td>
<td>3.5</td>
</tr>
<tr>
<td>HIV prevalence (%) among men who have sex with men</td>
<td>0.40000001</td>
<td>-</td>
<td>0.40000001</td>
</tr>
<tr>
<td>Estimated number of people living with HIV [95% UI]</td>
<td>-</td>
<td>-</td>
<td>4000 [3100-4900]</td>
</tr>
<tr>
<td>Estimated number of adults (15+ yrs) living with HIV [95% UI]</td>
<td>2900 [2200-3600]</td>
<td>1100 [1000-1300]</td>
<td>3900 [3100-4900]</td>
</tr>
<tr>
<td>Estimated number of AIDS-related deaths [95% UI]</td>
<td>-</td>
<td>-</td>
<td>&lt;100 [100-&lt;100]</td>
</tr>
</tbody>
</table>

Data accessed on 12 Nov 2019

Crude adjusted prevalence (%) estimate of tobacco use among people aged ≥15 years by country, for the year 2016.

"Current" means smoking at the time of the survey, including both daily and non-daily or occasional smoking. "Tobacco smoking" means smoking any form of tobacco, including cigarettes, cigars, pipes, or any other smoked tobacco products and excluding smokeless products.

"Daily" means smoking every day at the time of the survey. "Tobacco smoking" means smoking any form of tobacco, including cigarettes, cigars, pipes, or any other smoked tobacco products and excluding smokeless products.

"Current" means smoking at the time of the survey, including both daily and non-daily or occasional smoking.

"Daily" means smoking every day at the time of the survey.

Year of estimate: 2016

Data Sources:


2 Rapid HIV tests done anonymously and free of charge in Finnish AIDS Council’s service points in Helsinki, Tampere, Turku and Oulu during 2013.
6 Sexual and reproductive health behaviour indicators

Sexual intercourse is the primary route of transmission of genital HPV infection. Information about sexual and reproductive health behaviours is essential to the design of effective preventive strategies against anogenital cancers. In this section, we describe sexual and reproductive health indicators that may be used as proxy measures of risk for HPV infection and anogenital cancers. Several studies have reported that earlier sexual debut is a risk factor for HPV infection, although the reason for this relationship is still unclear. In this section, information on sexual and reproductive health behaviour in Finland are presented.

### Table 40: Percentage of 15-year-olds who have had sexual intercourse in Finland

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage of 15-year-old subjects who report sexual intercourse</td>
<td>25.0</td>
<td>24.0</td>
</tr>
</tbody>
</table>

**Data accessed on 16 Mar 2017**

Please refer to original source for methods of estimation.

Fifteen-year-olds teenagers only were asked whether they had ever had sexual intercourse.

**Year of estimation:** 2013-2014

**Data Sources:**

### Table 41: Median age at first sex in Finland

<table>
<thead>
<tr>
<th>Study, Year</th>
<th>Birth cohort</th>
<th>N</th>
<th>Male Median age at first sex</th>
<th>Female Median age at first sex</th>
<th>Total Median age at first sex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hubert 1998</td>
<td>1972-1973</td>
<td>46</td>
<td>18.0</td>
<td>40</td>
<td>16.6</td>
</tr>
<tr>
<td>Hubert 1998</td>
<td>1982-1984</td>
<td>134</td>
<td>18.7</td>
<td>149</td>
<td>20.0</td>
</tr>
<tr>
<td>Hubert 1998</td>
<td>1962-1966</td>
<td>123</td>
<td>17.3</td>
<td>109</td>
<td>17.8</td>
</tr>
<tr>
<td>Hubert 1998</td>
<td>1967-1971</td>
<td>113</td>
<td>18.0</td>
<td>121</td>
<td>18.0</td>
</tr>
</tbody>
</table>

**Data accessed on 16 Mar 2017**

Please refer to original source for methods of estimation.

**Year of estimation:** 2013-2014

**Data Sources:**
### Table 42: Marriage patterns in Finland

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average age at first marriage(^1)</td>
<td>31.9</td>
<td>30.1</td>
</tr>
<tr>
<td>Age-specific % of ever married(^2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-19 years</td>
<td>0.07</td>
<td>0.3</td>
</tr>
<tr>
<td>20-24 years</td>
<td>3</td>
<td>6.28</td>
</tr>
<tr>
<td>25-29 years</td>
<td>15.6</td>
<td>25.62</td>
</tr>
<tr>
<td>30-34 years</td>
<td>37.8</td>
<td>50.45</td>
</tr>
<tr>
<td>35-39 years</td>
<td>54.56</td>
<td>65.32</td>
</tr>
<tr>
<td>40-44 years</td>
<td>64.45</td>
<td>72.67</td>
</tr>
<tr>
<td>45-49 years</td>
<td>68.46</td>
<td>75.18</td>
</tr>
<tr>
<td>50-54 years</td>
<td>72.06</td>
<td>78.15</td>
</tr>
<tr>
<td>55-59 years</td>
<td>75.47</td>
<td>81.68</td>
</tr>
<tr>
<td>60-64 years</td>
<td>79.97</td>
<td>85.39</td>
</tr>
<tr>
<td>65-69 years</td>
<td>85.28</td>
<td>89.17</td>
</tr>
<tr>
<td>70-74 years</td>
<td>89.65</td>
<td>91.41</td>
</tr>
<tr>
<td>(+75)</td>
<td>92.45</td>
<td>91.73</td>
</tr>
</tbody>
</table>

Data accessed on 20 Feb 2020

Please refer to original source for methods of estimation.


\(^2\) UNSD

Data Sources:


### Table 43: Average number of sexual partners in Finland

<table>
<thead>
<tr>
<th>Study</th>
<th>Period of estimate</th>
<th>Year/Period</th>
<th>Birth cohort</th>
<th>Male Mean(N)</th>
<th>Female Mean(N)</th>
<th>Total Mean(N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(-)</td>
<td>(-)</td>
<td>(-)</td>
</tr>
</tbody>
</table>

Data accessed on 8 Aug 2013

Please refer to original source for methods of estimation.
Table 44: Lifetime prevalence of anal intercourse among women in Finland

<table>
<thead>
<tr>
<th>Studya</th>
<th>Year/Period</th>
<th>Birth cohort</th>
<th>N surveyed</th>
<th>N sexual active</th>
<th>% among sexually active</th>
</tr>
</thead>
</table>

Data accessed on 8 Aug 2013

Please refer to original source for methods of estimation.

Data Sources:

7 HPV preventive strategies

It is established that well-organised cervical screening programmes or widespread good quality cytology can reduce cervical cancer incidence and mortality. The introduction of HPV vaccination could also effectively reduce the burden of cervical cancer in the coming decades. This section presents indicators on basic characteristics and performance of cervical cancer screening, status of HPV vaccine licensure and introduction in Finland.

7.1 Cervical cancer screening practices

Screening strategies differ between countries. Some countries have population-based programmes, where in each round of screening women in the target population are individually identified and invited to attend screening. This type of programme can be implemented nationwide or only in specific regions of the country. In opportunistic screening, invitations depend on the individual’s decision or on encounters with health-care providers. The most frequent method for cervical cancer screening is cytology, and there are alternative methods such as HPV DNA tests and visual inspection with acetic acid (VIA). VIA is an alternative to cytology-based screening in low-resource settings (the ‘see and treat’ approach). HPV DNA testing is being introduced into some countries as an adjunct to cytology screening (‘co-testing’) or as the primary screening test to be followed by a secondary, more specific test, such as cytology.

Table 45: Main characteristics of cervical cancer screening in Finland

| Availability of a cervical cancer screening programme | Yes |
| Quality assurance structure and mandate to supervise and to monitor the screening process | Yes |
| Active invitation to screening | Yes |
| Main screening test used for primary screening | Cytology |
| Undergoing demonstration projects | - |
| Screening ages (years) | 30-60 |
| Screening interval or frequency of screenings | 5 years |

Data accessed on 31 Dec 2016

1,2,3 Public national cervical cancer screening program in place (Cytology/VIA/HPV testing). Countries may have clinical guidelines or protocols, and cervical cancer screening services in a private sector but without a public national program. Publicly mandated programmes have a law, official regulation, decision, directive or recommendation that provides the public mandate to implement the programme with an authorised screening test, examination interval, target group and funding and co-payment determined.

4,5 Self-reported quality assurance: Organised programmes provide for a national or regional team responsible for implementation and require providers to follow guidelines, rules, or standard operating procedures. They also define a quality assurance structure and mandate supervision and monitoring of the screening process. To evaluate impact, organised programmes also require ascertainment of the population disease burden. Quality assurance consists of the management and coordination of the programme throughout all levels of the screening process (invitation, testing, diagnosis and follow-up of screen-positives) to assure that the programme performs adequately and provides services that are effective and in-line with programme standards. The quality assurance structure is self-reported as part of the national cancer programs or plans.

6 Self-reported active invitation or recruitment, as organised population-based programmes, identify and personally invite each eligible person in the target population to attend a given round of screening.

Table 46: Estimated coverage of cervical cancer screening in Finland

<table>
<thead>
<tr>
<th>Reference</th>
<th>Year</th>
<th>Population</th>
<th>Urban vs rural or both (all)</th>
<th>N Women</th>
<th>Age range</th>
<th>Within the last year(s)</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Registry Finland1,2</td>
<td>2005</td>
<td>National screening programme</td>
<td>All</td>
<td>236690</td>
<td>30-60</td>
<td>5y</td>
<td>69.6</td>
</tr>
<tr>
<td>Cancer Registry Finland3,4</td>
<td>2012</td>
<td>National screening programme</td>
<td>All</td>
<td>273915</td>
<td>20-65</td>
<td>5y</td>
<td>52</td>
</tr>
<tr>
<td>EUROSTAT Finland3,4</td>
<td>2001</td>
<td>National screening programme</td>
<td>All</td>
<td>-</td>
<td>30-60</td>
<td>1y</td>
<td>70.3</td>
</tr>
<tr>
<td></td>
<td>2002</td>
<td>National screening programme</td>
<td>All</td>
<td>-</td>
<td>30-60</td>
<td>1y</td>
<td>72</td>
</tr>
</tbody>
</table>

Data Sources:


Continued on next page
Table 46 – continued from previous page

<table>
<thead>
<tr>
<th>Reference</th>
<th>Year</th>
<th>Population</th>
<th>Urban vs rural (both (all))</th>
<th>N Women</th>
<th>Age range</th>
<th>Within the last year(s)</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OECD Health Data 2007,4,6</td>
<td>2001</td>
<td>General female population</td>
<td>All</td>
<td>30-60</td>
<td>1y</td>
<td>72.2</td>
<td></td>
</tr>
<tr>
<td>OECD Health Data 2007,4,6</td>
<td>2002</td>
<td>General female population</td>
<td>All</td>
<td>30-60</td>
<td>1y</td>
<td>71.6</td>
<td></td>
</tr>
<tr>
<td>OECD Health Data 2007,4,6</td>
<td>2003</td>
<td>General female population</td>
<td>All</td>
<td>30-60</td>
<td>1y</td>
<td>71.4</td>
<td></td>
</tr>
<tr>
<td>OECD Health Data 2007,4,6</td>
<td></td>
<td>National screening programme</td>
<td>All</td>
<td>30-60</td>
<td>1y</td>
<td>70.7</td>
<td></td>
</tr>
<tr>
<td>OECD Health Data 2007,4,6</td>
<td></td>
<td>National screening programme</td>
<td>All</td>
<td>30-60</td>
<td>1y</td>
<td>69.7</td>
<td></td>
</tr>
<tr>
<td>OECD Health Data 2007,4,6</td>
<td></td>
<td>National screening programme</td>
<td>All</td>
<td>30-60</td>
<td>1y</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>OECD Health Data 2007,4,6</td>
<td></td>
<td>National screening programme</td>
<td>All</td>
<td>30-60</td>
<td>1y</td>
<td>69.8</td>
<td></td>
</tr>
<tr>
<td>WHO Household Surveys with multistage cluster sampling 2003-2007</td>
<td>2002-2003</td>
<td>General female population</td>
<td>Rural</td>
<td>185</td>
<td>18-69</td>
<td>1y</td>
<td>64.4</td>
</tr>
<tr>
<td>WHO Household Surveys with multistage cluster sampling 2003-2007</td>
<td>2002-2003</td>
<td>General female population</td>
<td>Rural</td>
<td>185</td>
<td>18-69</td>
<td>1y</td>
<td>64.4</td>
</tr>
</tbody>
</table>

Data accessed on 31 Dec 2016

a HPV - Data from The Finnish Cancer Registry. The screening interval is five years, and it covers the population between 30 and 60 years of age. The Finnish health information system collects information on cancer screening from individuals, based on issued personal invitations to undergo screening. The help of personal identification numbers, it is possible to follow up all invited women to establish how many participated in the cancer screening. In 2005, 97% of women aged 30-60 years of age were invited for organised cervical cancer screening and 69% participated (71% of those invited). In addition, some municipalities also invited women aged 20 (1% invited) or 25 years (35% invited), respectively. Finnish public health (until end of 2006) and screening statutes (since 2007): the screening interval is five years, and it covers the population between 30 and 60 years of age. The Finnish health information system collects information on cancer screening from individuals, based on issued personal invitations to undergo screening. The help of personal identification numbers, it is possible to follow up all invited women to establish how many participated in the cancer screening. In 2005, 97% of women aged 30-60 years of age were invited for organised cervical cancer screening and 69% participated (71% of those invited). In addition, some municipalities also invited women aged 20 (1% invited) or 25 years (35% invited) and 43% and 57% of those invited participated, respectively. Garcia Armesto S., Gil Lapetra M.L., Wei L., Kelleyand E., and the Members of the HCQI Expert Group. Health Care Quality Indicators Project 2006 Data Collection Update Report. Paris; France: Organisation for Economic Co-operation and Development (OECD); 2007. Report No.: DELSA/HEA/WD/HWP(2007)4; OECD HEALTH WORKING PAPERS NO. 20.

b Programme data. Finland National Cancer Registry. Women aged 30-60 years old invited through the organised cervical cancer screening during the reporting year.

c Programme data. All data is from The Finnish Cancer Registry. The screening interval is five years, and it covers the population between 30 and 60 years of age. The Finnish health information system collects information on cancer screening from individuals, based on issued personal invitations to undergo screening. The help of personal identification numbers, it is possible to follow up all invited women to establish how many participated in the cancer screening. In 2005, 97% of women aged 30-60 years of age were invited for organised cervical cancer screening and 69% participated (71% of those invited). In addition, some municipalities also invited women aged 20 (1% invited) or 25 years (35% invited) and 43% and 57% of those invited participated, respectively. Finnish public health (until end of 2006) and screening statutes (since 2007): the screening interval is five years, and it covers the population between 30 and 60 years of age. The Finnish health information system collects information on cancer screening from individuals, based on issued personal invitations to undergo screening. The help of personal identification numbers, it is possible to follow up all invited women to establish how many participated in the cancer screening. In 2005, 97% of women aged 30-60 years of age were invited for organised cervical cancer screening and 69% participated (71% of those invited). In addition, some municipalities also invited women aged 20 (1% invited) or 25 years (35% invited) and 43% and 57% of those invited participated, respectively.


ICO/IARC HPV Information Centre
Data Sources:


Figure 70: Estimated coverage of cervical cancer screening in Finland, by age and study

Data accessed on 31 Dec 2016

- All women screened every 5y in 2005 - (1, b)
- All women screened every 5y in 2012 - (2, b)
- All women screened every 3y in 2002-2003 - (3, c)

Table 47: Estimated coverage of cervical cancer screening in Finland, by region

<table>
<thead>
<tr>
<th>Region</th>
<th>N Women</th>
<th>Age range</th>
<th>LYa</th>
<th>Population</th>
<th>Coverage (%)b</th>
<th>Year(s) studied</th>
<th>Reference</th>
</tr>
</thead>
</table>

Data accessed on 31 Dec 2016

- LY: Within the last year(s)
- Proportion of women in the total sample of the mentioned age range in the country or region that reported having a Pap smear during a given time period (e.g., last year, last 2, 3, 5 years or ever).
7.2 HPV vaccination

Table 48: National HPV Immunization programme in Finland

<table>
<thead>
<tr>
<th>HPV vaccination programme</th>
<th>Female</th>
<th>Male</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Introduced</td>
<td>Not Available, Not Introduced/No Plans</td>
</tr>
<tr>
<td>Year of introduction</td>
<td>2013</td>
<td>-</td>
</tr>
<tr>
<td>HPV coverage – first dose (%) (estimation year 2019)</td>
<td>60(^a)</td>
<td>-</td>
</tr>
<tr>
<td>HPV coverage – last dose (%) (estimation year 2019)</td>
<td>60(^b)</td>
<td>-</td>
</tr>
<tr>
<td>HPV coverage – first dose (%) (estimation year 2020)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HPV coverage – last dose (%) (estimation year 2020)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Data accessed on 20 Sep 2021
\(^a\) Estimate based on reported official coverage for the final dose. Coverage may be underestimated
\(^b\) Estimate based on reported coverage from the national vaccination registry.

Data Sources:

7.2.1 HPV vaccination in Finland, by region

Table 49: National HPV Immunization programme in - (Finland)

<table>
<thead>
<tr>
<th>HPV vaccination programme</th>
<th>Female</th>
<th>Male</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data accessed on 31 Oct 2014
\(^a\) 2 doses: 0-6m if not otherwise stated. Since 2014, based on clinical trials results several agencies responsible for the scientific evaluation of medicines, like the European Medicines Agency, approved a two-dose schedule for girls aged less than 15 or 14 depending on the vaccine (Cervarix or Gardasil).
\(^b\) 3-doses standard: administration of three doses following the standard vaccination schedule as 0-2-6 months for the quadrivalent vaccine or 0-1-6 months for the bivalent vaccine.

Data Sources:
Adapted from Bruni et al 2016 Lancet Global Health (data up to October 2014).

Figure 71: Reported HPV vaccination coverage in females by birth cohort in National HPV Immunization programme in - (Finland)

Data accessed on 31 Oct 2014
Red circle: One coverage, Green triangle: Full coverage
Data Sources:
Adapted from Bruni et al 2016 Lancet Global Health (data up to October 2014).
8 Protective factors for cervical cancer

Male circumcision and the use of condoms have shown a significant protective effect against HPV transmission.

Table 50: Prevalence of male circumcision in Finland

<table>
<thead>
<tr>
<th>Reference</th>
<th>Prevalence % (95% CI)</th>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO 2007</td>
<td>&lt;20</td>
<td>Data from Demographic and Health Surveys (DHS) and other publications to categorize the country-wide prevalence of male circumcision as &lt;20%, 20-80%, or &gt;80%.</td>
</tr>
</tbody>
</table>

Data accessed on 31 Aug 2015
Please refer to country-specific reference(s) for full methodologies.

Data Sources:
WHO 2007: Male circumcision: Global trends and determinants of prevalence, safety and acceptability
Based on systematic reviews and meta-analysis performed by ICo. The ICo HPV Information Centre has updated data until August 2015. Reference publication: Albero G, Sex Transm Dis. 2012 Feb;39(2):104-13.

Table 51: Prevalence of condom use in Finland

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Age range</th>
<th>Year of estimate</th>
<th>Prevalence %a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condom use</td>
<td>18-49</td>
<td>2015</td>
<td>30.7262569832402</td>
</tr>
</tbody>
</table>

Data accessed on 18 Nov 2019
Please refer to original source for methods of estimation.

Data Sources:
2015 SS
9 Annex

9.1 Incidence

9.1.1 Cervical cancer incidence in Finland across Northern Europe

Figure 72: Age-standardised incidence rates of cervical cancer of Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Rates per 100,000 women per year.

Data Sources
Figure 73: Annual number of new cases of cervical cancer by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-source-methods

Data Sources:

ICO/IARC HPV Information Centre
Figure 74: Comparison of age-specific cervical cancer incidence rates in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021

Rates per 100,000 women per year.

Data Sources
9.1.2 Anal cancer incidence in Finland across Northern Europe

Figure 75: Age-standardised incidence rates of anal cancer of Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Country</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denmark</td>
<td>0.77</td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>0.93</td>
<td></td>
</tr>
<tr>
<td>Norway</td>
<td>0.55</td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>0.61</td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td>0.33</td>
<td>0.92</td>
</tr>
<tr>
<td>Ireland</td>
<td>0.64</td>
<td>0.79</td>
</tr>
<tr>
<td>Latvia</td>
<td>0.32</td>
<td>0.70</td>
</tr>
<tr>
<td>Finland</td>
<td>0.40</td>
<td>0.48</td>
</tr>
<tr>
<td>Lithuania</td>
<td>0.45</td>
<td>0.42</td>
</tr>
<tr>
<td>Iceland</td>
<td>*</td>
<td>0.29</td>
</tr>
</tbody>
</table>

Anal cancer: Age-standardised incidence rate per 100,000 men and women
World Standard. Male and Female (All ages)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-surveillance-methods

Rates per 100,000 men per year.

Rates per 100,000 women per year.

Rates are not available.

Data Sources:
Figure 76: Annual number of new cases of anal cancer among men by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group. 0 cases for Finland and 3 cases for Northern Europe in the 30-34 age group.

Data Sources:
Figure 77: Annual number of new cases of anal cancer among women by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group. 0 cases for Finland and 8 cases for Northern Europe in the 30-34 age group.

Data Sources:
Figure 78: Comparison of age-specific anal cancer incidence rates among men by age in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-source-methods
* Rates per 100,000 men per year.

Data Sources
Figure 79: Comparison of age-specific anal cancer incidence rates among women by age in Finland, within the region, and the rest of world

<table>
<thead>
<tr>
<th>Age group (years)</th>
<th>Finland</th>
<th>Northern Europe</th>
<th>World</th>
</tr>
</thead>
<tbody>
<tr>
<td>15-19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25-29</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30-34</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35-39</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40-44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-49</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50-54</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55-59</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60-64</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-69</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>70-74</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-79</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>80-84</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021


Data Sources:
9.1.3 Vulva cancer incidence in Finland across Northern Europe

Figure 80: Age-standardised incidence rates of vulva cancer of Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources
Figure 81: Annual number of new cases of vulva cancer by age group in Finland (estimates for 2020)

Data sources:
Figure 82: Comparison of age-specific vulva cancer incidence rates in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
*Rates per 100,000 women per year.

Data Sources
9.1.4 Vaginal cancer incidence in Finland across Northern Europe

Figure 83: Age-standardised incidence rates of vaginal cancer of Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

<table>
<thead>
<tr>
<th>Country</th>
<th>Incidence Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latvia</td>
<td>0.47</td>
</tr>
<tr>
<td>Estonia</td>
<td>0.46</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>0.43</td>
</tr>
<tr>
<td>Iceland</td>
<td>0.41</td>
</tr>
<tr>
<td>Lithuania</td>
<td>0.36</td>
</tr>
<tr>
<td>Finland</td>
<td>0.31</td>
</tr>
<tr>
<td>Ireland</td>
<td>0.31</td>
</tr>
<tr>
<td>Denmark</td>
<td>0.29</td>
</tr>
<tr>
<td>Sweden</td>
<td>0.26</td>
</tr>
<tr>
<td>Norway</td>
<td>0.24</td>
</tr>
</tbody>
</table>

Rates per 100,000 women per year.

Data Sources:
Figure 84: Annual number of new cases of cervical cancer by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021


0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 1 case for Northern Europe in the 20-24 age group. 0 cases for Finland and 3 cases for Northern Europe in the 25-29 age group. 0 cases for Finland and 1 case for Northern Europe in the 30-34 age group.

Data Sources:
Figure 85: Comparison of age-specific vaginal cancer incidence rates in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
\( ^{a} \) Rates per 100,000 women per year.

Data Sources:
9.1.5 Penile cancer incidence in Finland across Northern Europe

Figure 86: Age-standardised incidence rates of penile cancer of Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Rates per 100,000 men per year.

Data Sources
Figure 87: Annual number of new cases of penile cancer by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-source-methods

0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 1 cases for Northern Europe in the 25-29 age group. 1 cases for Finland and 2 cases for Northern Europe in the 30-34 age group.

Data Sources:
Figure 88: Comparison of age-specific penile cancer incidence rates in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

* Rates per 100,000 men per year.

Data Sources:
9.1.6 Oropharyngeal cancer incidence in Finland across Northern Europe

Figure 89: Age-standardised incidence rates of oropharyngeal cancer of Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more-detailed methods of estimation please refer to http://gco.iarc.fr/today/data-source-methods

- Rates per 100,000 men per year.
- Rates per 100,000 women per year.
- Rates are not available

Data Source:
Figure 90: Annual number of new cases of oropharyngeal cancer among men by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

* 0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group.
* 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group.
* 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group.
* 1 case for Finland and 3 cases for Northern Europe in the 30-34 age group.
* 4 cases for Finland and 24 cases for Northern Europe in the 85+ age group.

Data Sources:
Figure 91: Annual number of new cases of oropharyngeal cancer among women by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

* 0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group. 0 cases for Finland and 1 cases for Northern Europe in the 30-34 age group.

Data Sources:
Figure 92: Comparison of age-specific oropharyngeal cancer incidence rates among men by age in Finland, within the region, and the rest of world.
Figure 93: Comparison of age-specific oropharyngeal cancer incidence rates among women by age in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Rates per 100,000 women per year.

Data Sources:
9.1.7 Oral cavity cancer incidence in Finland across Northern Europe

Figure 94: Age-standardised incidence rates of oral cavity cancer of Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Country</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>United Kingdom</td>
<td>6.77</td>
<td>3.50</td>
</tr>
<tr>
<td>Denmark</td>
<td>4.33</td>
<td>2.81</td>
</tr>
<tr>
<td>Sweden</td>
<td>3.41</td>
<td>2.76</td>
</tr>
<tr>
<td>Ireland</td>
<td>5.32</td>
<td>2.63</td>
</tr>
<tr>
<td>Norway</td>
<td>4.48</td>
<td>2.59</td>
</tr>
<tr>
<td>Finland</td>
<td>3.76</td>
<td>2.23</td>
</tr>
<tr>
<td>Estonia</td>
<td>4.76</td>
<td>1.74</td>
</tr>
<tr>
<td>Lithuania</td>
<td>6.55</td>
<td>1.42</td>
</tr>
<tr>
<td>Latvia</td>
<td>12.3</td>
<td>1.31</td>
</tr>
<tr>
<td>Iceland</td>
<td>2.49</td>
<td>1.12</td>
</tr>
</tbody>
</table>

Oral cavity cancer: Age-standardised incidence rate per 100,000 men and women
World Standard. Male and Female (All ages)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Rates per 100,000 men per year.

Rates per 100,000 women per year.

Data Sources:
Figure 95: Annual number of new cases of oral cavity cancer among men by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

For 0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 1 cases for Finland and 3 cases for Northern Europe in the 20-24 age group. 1 cases for Finland and 3 cases for Northern Europe in the 25-29 age group. 1 cases for Finland and 26 cases for Northern Europe in the 30-34 age group.

Data Sources
Figure 96: Annual number of new cases of oral cavity cancer among women by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

0 cases for Finland and 1 cases for Northern Europe in the 15-19 age group.
0 cases for Finland and 1 cases for Northern Europe in the 20-24 age group.
1 cases for Finland and 11 cases for Northern Europe in the 25-29 age group.
1 cases for Finland and 25 cases for Northern Europe in the 30-34 age group.

Data Sources:
Figure 97: Comparison of age-specific oral cavity cancer incidence rates among men by age in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/dataSources-methods
* Rates per 100,000 men per year.

Data Sources
Figure 98: Comparison of age-specific oral cavity cancer incidence rates among women by age in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Rates per 100,000 women per year.

Data Sources:

ICO/IARC HPV Information Centre
9.1.8 Laryngeal cancer incidence in Finland across Northern Europe

Figure 99: Age-standardised incidence rates of laryngeal cancer of Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more-detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Rates per 100,000 men per year.

Rates per 100,000 women per year.

Data Sources:
Figure 100: Annual number of new cases of laryngeal cancer among men by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group. 0 cases for Finland and 0 cases for Northern Europe in the 30-34 age group. 0 cases for Finland and 9 cases for Northern Europe in the 35-39 age group.

Data Sources:
Figure 101: Annual number of new cases of laryngeal cancer among women by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021


0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group. 0 cases for Finland and 1 cases for Northern Europe in the 30-34 age group.

Data Sources:
Figure 102: Comparison of age-specific laryngeal cancer incidence rates among men by age in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-source-methods

Rates per 100,000 men per year.

Data Sources
Figure 103: Comparison of age-specific laryngeal cancer incidence rates among women by age in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Rates per 100,000 women per year.

Data Sources:
9.2 Mortality

9.2.1 Cervical cancer mortality in Finland across Northern Europe

Figure 104: Age-standardised mortality rates of cervical cancer of Finland (estimates for 2020)

![Bar chart showing age-standardised mortality rates of cervical cancer for different countries in Northern Europe.]

- Latvia: 6.80
- Lithuania: 6.67
- Estonia: 4.33
- Ireland: 2.77
- Denmark: 2.20
- Iceland: 1.94
- United Kingdom: 1.92
- Sweden: 1.79
- Norway: 1.75
- Finland: 1.12

Data accessed on 27 Jan 2021


Data Sources:
Figure 105: Annual number of deaths of cervical cancer by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021


0 cases for Finland and 6 cases for Northern Europe in the 15-19 age group.

Data Sources:
Figure 106: Comparison of age-specific cervical cancer mortality rates in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021

Rates per 100,000 women per year.

Data Sources:
9.2.2 Anal cancer mortality in Finland across Northern Europe

Figure 107: Age-standardised mortality rates of anal cancer of Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more-detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources
Figure 108: Annual number of deaths of anal cancer among men by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group. 0 cases for Finland and 1 cases for Northern Europe in the 30-34 age group. 0 cases for Finland and 2 cases for Northern Europe in the 35-39 age group.

Data Sources:
Figure 109: Annual number of deaths of anal cancer among women by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

* 0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group.
* 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group.
* 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group.
* 0 cases for Finland and 1 cases for Northern Europe in the 30-34 age group.
* 0 cases for Finland and 3 cases for Northern Europe in the 35-39 age group.

Data Sources:
Figure 110: Comparison of age-specific anal cancer mortality rates among men by age in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-source-methods
Rates per 100,000 men per year.

Data Sources
Figure 111: Comparison of age-specific anal cancer mortality rates among women by age in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Rates per 100,000 women per year.
Data Sources:

ICO/IARC HPV Information Centre
9.2.3 Vulva cancer mortality in Finland across Northern Europe

Figure 112: Age-standardised mortality rates of vulva cancer of Finland (estimates for 2020)

- Latvia: 0.54
- United Kingdom: 0.49
- Estonia: 0.45
- Sweden: 0.40
- Denmark: 0.39
- Lithuania: 0.37
- Norway: 0.37
- Ireland: 0.35
- Finland: 0.34
- Iceland: *

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
*Rates per 100,000 women per year.
* Rates are not available

Data Source:
Figure 113: Annual number of deaths of vulva cancer by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021


- 0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group.
- 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group.
- 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group.
- 0 cases for Finland and 1 cases for Northern Europe in the 30-34 age group.
- 0 cases for Finland and 1 cases for Northern Europe in the 35-39 age group.
- 0 cases for Finland and 3 cases for Northern Europe in the 40-44 age group.
- 0 cases for Finland and 7 cases for Northern Europe in the 45-49 age group.

Data Sources:
Figure 114: Comparison of age-specific vulva cancer mortality rates in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more-detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

* Rates per 100,000 women per year.

Data Sources
9.2.4 Vaginal cancer mortality in Finland across Northern Europe

Figure 115: Age-standardised mortality rates of vaginal cancer of Finland (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Rates per 100,000 women per year.

* Rates are not available

Data Sources:
Figure 116: Annual number of deaths of cervical cancer by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group. 0 cases for Finland and 0 cases for Northern Europe in the 30-34 age group. 0 cases for Finland and 1 cases for Northern Europe in the 35-39 age group.

Data Sources:
Figure 117: Comparison of age-specific vaginal cancer mortality rates in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data sources-methods
Rates per 100,000 women per year.
Data Sources:
9.2.5 Penile cancer mortality in Finland across Northern Europe

Figure 118: Age-standardised mortality rates of penile cancer of Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
* Rates are not available

Data Sources:
Figure 119: Annual number of new deaths of penile cancer by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021


Verbal data: 0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group. 1 cases for Finland and 2 cases for Northern Europe in the 30-34 age group. 0 cases for Finland and 2 cases for Northern Europe in the 35-39 age group. 0 cases for Finland and 2 cases for Northern Europe in the 40-44 age group.

Data Sources:
Figure 120: Comparison of age-specific penile cancer mortality rates in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
*Rates per 100,000 men per year.
Data Sources:
9.2.6 Oropharyngeal cancer mortality in Finland across Northern Europe

Figure 121: Age-standardised mortality rates of oropharyngeal cancer of Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
* Rates per 100,000 men per year.
* Rates per 100,000 women per year.
* Rates are not available

Data Sources
Figure 122: Annual number of deaths of oropharyngeal cancer among men by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group. 0 cases for Finland and 0 cases for Northern Europe in the 30-34 age group. 0 cases for Finland and 4 cases for Northern Europe in the 35-39 age group.

Data Sources:
Figure 123: Annual number of deaths of oropharyngeal cancer among women by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021


Data Sources:
Figure 124: Comparison of age-specific oropharyngeal cancer mortality rates among men by age in Finland, within the region, and the rest of world.
Figure 125: Comparison of age-specific oropharyngeal cancer mortality rates among women by age in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
*Rates per 100,000 women per year.

Data Sources
9.2.7 Oral cavity cancer mortality in Finland across Northern Europe

Figure 126: Age-standardised mortality rates of oral cavity cancer of Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more-detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources
Figure 127: Annual number of deaths of oral cavity cancer among men by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group. 1 case for Finland and 3 cases for Northern Europe in the 30-34 age group. 0 cases for Finland and 11 cases for Northern Europe in the 35-39 age group.

Data Sources:

ICO/IARC HPV Information Centre
Figure 128: Annual number of deaths of oral cavity cancer among women by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

* 0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 1 case for Northern Europe in the 25-29 age group. 1 cases for Finland and 3 cases for Northern Europe in the 30-34 age group. 1 cases for Finland and 6 cases for Northern Europe in the 35-39 age group. 1 cases for Finland and 11 cases for Northern Europe in the 40-44 age group.

Data Sources

Figure 129: Comparison of age-specific oral cavity cancer mortality rates among men by age in Finland, within the region, and the rest of world

---

Data accessed on 27 Jan 2021


* Rates per 100,000 men per year.

Data Sources

Figure 130: Comparison of age-specific oral cavity cancer mortality rates among women by age in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Rates per 100,000 women per year.

Data Sources
9.2.8 Laryngeal cancer mortality in Finland across Northern Europe

Figure 131: Age-standardised mortality rates of laryngeal cancer of Finland (estimates for 2020)

<table>
<thead>
<tr>
<th>Country</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iceland</td>
<td>2.6</td>
<td>0.19</td>
</tr>
<tr>
<td>Latvia</td>
<td>5.15</td>
<td>0.07</td>
</tr>
<tr>
<td>Lithuania</td>
<td>0.96</td>
<td>0.23</td>
</tr>
<tr>
<td>Norway</td>
<td>1.46</td>
<td>0.12</td>
</tr>
<tr>
<td>Poland</td>
<td>0.39</td>
<td>0.05</td>
</tr>
<tr>
<td>Sweden</td>
<td>0.61</td>
<td>0.05</td>
</tr>
<tr>
<td>Finland</td>
<td>3.91</td>
<td>0.07</td>
</tr>
</tbody>
</table>

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

* Rates per 100,000 men per year.
* Rates per 100,000 women per year.
* Rates are not available

Data Sources
Figure 132: Annual number of deaths of laryngeal cancer among men by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group. 0 cases for Finland and 0 cases for Northern Europe in the 30-34 age group. 0 cases for Finland and 1 cases for Northern Europe in the 35-39 age group. 0 cases for Finland and 8 cases for Northern Europe in the 40-44 age group.

Data Sources

Figure 133: Annual number of deaths of laryngeal cancer among women by age group in Finland (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

0 cases for Finland and 0 cases for Northern Europe in the 15-19 age group. 0 cases for Finland and 0 cases for Northern Europe in the 20-24 age group. 0 cases for Finland and 0 cases for Northern Europe in the 25-29 age group. 0 cases for Finland and 1 cases for Northern Europe in the 30-34 age group. 0 cases for Finland and 1 cases for Northern Europe in the 35-39 age group. 0 cases for Finland and 1 cases for Northern Europe in the 40-44 age group.

Data Sources:

Figure 134: Comparison of age-specific laryngeal cancer mortality rates among men by age in Finland, within the region, and the rest of world

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Rates per 100,000 men per year.

Data Sources:

ICO/IARC HPV Information Centre
Figure 135: Comparison of age-specific laryngeal cancer mortality rates among women by age in Finland, within the region, and the rest of the world.

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

* Rates per 100,000 women per year.

### 10 Glossary

**Table 52: Glossary**

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence</td>
<td>Incidence is the number of new cases arising in a given period in a specified population. This information is collected routinely by cancer registries. It can be expressed as an absolute number of cases per year or as a rate per 100,000 persons per year (see Crude rate and ASR below). The rate provides an approximation of the average risk of developing a cancer.</td>
</tr>
<tr>
<td>Mortality</td>
<td>Mortality is the number of deaths occurring in a given period in a specified population. It can be expressed as an absolute number of deaths per year or as a rate per 100,000 persons per year.</td>
</tr>
<tr>
<td>Prevalence</td>
<td>The prevalence of a particular cancer can be defined as the number of persons in a defined population who have been diagnosed with that type of cancer, and who are still alive at the end of a given year, the survivors. Complete prevalence represents the number of persons alive at certain point in time who previously had a diagnosis of the disease, regardless of how long ago the diagnosis was, or if the patient is still under treatment or is considered cured. Partial prevalence, which limits the number of patients to those diagnosed during a fixed time in the past, is a particularly useful measure of cancer burden. Prevalence of cancers based on cases diagnosed within one, three and five are presented as they are likely to be of relevance to the different stages of cancer therapy, namely, initial treatment (one year), clinical follow-up (three years) and cure (five years). Patients who are still alive five years after diagnosis are usually considered cured since the death rates of such patients are similar to those in the general population. There are exceptions, particularly breast cancer. Prevalence is presented for the adult population only (ages 15 and over), and is available both as numbers and as proportions per 100,000 persons.</td>
</tr>
<tr>
<td>Crude rate</td>
<td>Data on incidence or mortality are often presented as rates. For a specific tumour and population, a crude rate is calculated simply by dividing the number of new cancers or cancer deaths observed during a given time period by the corresponding number of person years in the population at risk. For cancer, the result is usually expressed as an annual rate per 100,000 persons at risk.</td>
</tr>
<tr>
<td>ASR (age-standardised rate)</td>
<td>An age-standardised rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age because age has a powerful influence on the risk of cancer. The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the standard population. The most frequently used standard population is the World Standard Population. The calculated incidence or mortality rate is then called age-standardised incidence or mortality rate (world). It is also expressed per 100,000. The world standard population used in GLOBOCAN is as proposed by Segi [1] and modified by Doll and al. [2]. The age-standardised rate is calculated using 10 age-groups. The result may be slightly different from that computed using the same data categorised using the traditional 5 year age bands.</td>
</tr>
</tbody>
</table>

Continued on next page
<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cumulative risk</td>
<td>Cumulative incidence/mortality is the probability or risk of individuals getting/dying from the disease during a specified period. For cancer, it is expressed as the number of new born children (out of 100, or 1000) who would be expected to develop/die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.</td>
</tr>
<tr>
<td>Cytologically normal women</td>
<td>No abnormal cells are observed on the surface of their cervix upon cytology.</td>
</tr>
<tr>
<td>Cervical Intraepithelial Neoplasia (CIN) / Squamous Intraepithelial Lesions (SIL)</td>
<td>SIL and CIN are two commonly used terms to describe precancerous lesions or the abnormal growth of squamous cells observed in the cervix. SIL is an abnormal result derived from cervical cytological screening or Pap smear testing. CIN is a histological diagnosis made upon analysis of cervical tissue obtained by biopsy or surgical excision. The condition is graded as CIN 1, 2 or 3, according to the thickness of the abnormal epithelium (1/3, 2/3 or the entire thickness).</td>
</tr>
<tr>
<td>Low-grade cervical lesions (LSIL/CIN-1)</td>
<td>Low-grade cervical lesions are defined by early changes in size, shape, and number of abnormal cells formed on the surface of the cervix and may be referred to as mild dysplasia, LSIL, or CIN-1.</td>
</tr>
<tr>
<td>High-grade cervical lesions (HSIL / CIN-2 / CIN-3 / CIS)</td>
<td>High-grade cervical lesions are defined by a large number of precancerous cells on the surface of the cervix that are distinctly different from normal cells. They have the potential to become cancerous cells and invade deeper tissues of the cervix. These lesions may be referred to as moderate or severe dysplasia, HSIL, CIN-2, CIN-3 or cervical carcinoma in situ (CIS).</td>
</tr>
<tr>
<td>Carcinoma in situ (CIS)</td>
<td>Preinvasive malignancy limited to the epithelium without invasion of the basement membrane. CIN 3 encompasses the squamous carcinoma in situ.</td>
</tr>
<tr>
<td>Invasive cervical cancer (ICC) / Cervical cancer</td>
<td>If the high-grade precancerous cells invade the basement membrane is called ICC. ICC stages range from stage I (cancer is in the cervix or uterus only) to stage IV (the cancer has spread to distant organs, such as the liver).</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>Invasive tumour with glandular and squamous elements intermingled</td>
</tr>
</tbody>
</table>
Acknowledgments

This report has been developed by the Unit of Infections and Cancer, Cancer Epidemiology Research Program, at the Institut Català d‘Oncologia (ICO, Catalan Institute of Oncology). This report was supported by a grant from the Instituto de Salud Carlos III (Spanish Government) through the projects PI18/01137 and CIBERESP CB06/02/0073, and the Secretariat for Universities and Research of the Department of Business and knowledge of the Government of Catalonia grants to support the activities of research groups (SGR 2017–2019) (Grant number 2017SGR1718). The report has also received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 847845. We thank the CERCA Program / Generalitat de Catalunya for institutional support. The HPV Information Centre is being developed by the ICO. The Centre was originally launched by ICO with the collaboration of WHO’s Immunisation, Vaccines and Biologicals (IVB) department and support from the Bill and Melinda Gates Foundation.

Institut Català d‘Oncologia (ICO), in alphabetic order

International Agency for Research on Cancer (IARC)

Note to the reader

Anyone who is aware of relevant published data that may not have been included in the present report is encouraged to contact the HPV Information Centre for potential contributions. Although efforts have been made by the HPV Information Centre to prepare and include as accurately as possible the data presented, mistakes may occur. Readers are requested to communicate any errors to the HPV Information Centre, so that corrections can be made in future volumes.

Disclaimer

The information in this database is provided as a service to our users. Any digital or printed publication of the information provided in the web site should be accompanied by an acknowledgment of HPV Information Centre as the source. Systematic retrieval of data to create, directly or indirectly, a scientific publication, collection, database, directory or website requires a permission from HPV Information Centre.

The responsibility for the interpretation and use of the material contained in the HPV Information Centre lies on the user. In no event shall the HPV Information Centre be liable for any damages arising from the use of the information.

Licensed Logo Use

Use, reproduction, copying, or redistribution of HPV Information Centre logo is strictly prohibited without written explicit permission from the HPV Information Centre.

Contact information:

ICO/IARC HPV Information Centre
Institut Català d’Oncologia
Avda. Gran Vía de l’Hospitalat, 199-203
08908 L’Hospitalet de Llobregat (Barcelona, Spain)
e-mail: info@hpvcentre.net
internet address: www.hpvcentre.net